Sunil S Dhawan, MD
Dermatology · Milpitas
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 36
- 10 carriers
- Office
- 1
Offices
1 location · East Bay Dermatology Medical Group Inc. · 8 clinicians in this group
Hospitals listed: Washington Hospital. That is not proof they admit you there this week.
Plans that list them
36 plans · 10 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Dhawan’s office at (408) 957-7676 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
36 of 36 plans
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G53340 · Current
Licensed to practise in California · since 1984 · expires 2028-04-30 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Washington HospitalFremont, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Washington Hospital Healthcare SystemPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.188, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.164, Oct 2024 – Sep 2025
See every measure and the patient survey for Washington Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.188 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.164 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.88) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.59 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.95 (139.54 to 246.36) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 164 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 199 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 661 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 174 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 2,550 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.35) · 6,970 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,108 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.82 (1.73 to 5.91) · 1,370 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.52 (0 to 3.17) · 589 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.75 (0.25 to 3.25) · 1,315 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.19 (5.83 to 20.56) · 600 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.91 (1.04 to 8.78) · 550 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 6,079 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 114 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.367 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 480 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 33.9 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.5 · 553 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.8 · 648 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 590 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.2 to 6.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.5 to 14.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.1 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 202 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.2 to 18.5) · 78 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 974 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$430,997
Medicare paid this office $430,997 for 1,258 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 794 | $98,675 | $75 |
| Treatment of inflammatory skin disease using laser, less than 250.0 sq cm | 22 | $42,247 | $158 |
| Return visit (30+ min) | 177 | $30,589 | $109 |
| Destruction of skin growth, 1-14 growths | 205 | $30,474 | $108 |
| Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | 22 | $27,526 | $129 |
See all 31 services
| Short return visit (20+ min) | 794 | $98,675 | $75 |
| Treatment of inflammatory skin disease using laser, less than 250.0 sq cm | 22 | $42,247 | $158 |
| Return visit (30+ min) | 177 | $30,589 | $109 |
| Destruction of skin growth, 1-14 growths | 205 | $30,474 | $108 |
| Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | 22 | $27,526 | $129 |
| Destruction of precancer skin growth, 1 growth | 298 | $22,542 | $54 |
| Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | 68 | $18,845 | None |
| Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm | 16 | $18,382 | $170 |
| Short return visit | 252 | $15,756 | $48 |
| New patient visit (30+ min) | 186 | $15,756 | $85 |
| Application of light by qualified health care professional to destroy precancer skin growth | 60 | $13,783 | $222 |
| Punch biopsy, first skin growth | 82 | $10,081 | $115 |
| Destruction of precancer skin growth, 2-14 growths | 223 | $9,189 | $6 |
| Destruction of precancer skin growth, 15 or more growths | 31 | $6,354 | $163 |
| Biopsy of related skin growth, first growth | 58 | $5,767 | $95 |
| Injection into skin growth, 1-7 growths | 55 | $4,970 | $51 |
| Destruction of skin growth, 15 or more growths | 22 | $3,990 | $125 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 12 | $3,771 | $290 |
| New patient visit (45+ min) | 32 | $3,673 | $115 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 26 | $3,329 | $115 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | 13 | $2,979 | $229 |
| Simple or single drainage of skin abscess | 24 | $2,978 | $106 |
| New patient visit (15+ min) | 55 | $2,741 | $50 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 23 | $2,572 | $107 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | 19 | $2,091 | $105 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | 14 | $1,694 | $113 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 12 | $1,617 | $124 |
| Injection into skin growth, more than 7 growths | 13 | $1,268 | $55 |
| Biopsy of related skin growth, each additional growth | 14 | $725 | $52 |
| Injection of drug or substance under skin or into muscle | 13 | $255 | $14 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 65 | $126 | None |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 22 | More than 76% of doctors who do this |
| Removal of nail tissue | 1-10 | None |
| Removal of skin lesions | 1010 | More than 93% of doctors who do this |
| Removal of tissue | 1-10 | None |
| Removal or shaving of skin growth | 150 | More than 88% of doctors who do this |
| Skin biopsy | 132 | More than 79% of doctors who do this |
Who their Medicare patients are
1,258 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 14% · Women 51% · Also on Medicaid 34% · Health risk score 1.13. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 75% · Diabetes 38% · Coronary heart disease 26% · Chronic kidney disease 23% · Atrial fibrillation 15% · Heart failure 13% · Cancer 12% · Depression 12% · COPD 11% · Stroke 7% · Dementia 6%.
The office billed $1,260,826, Medicare allowed $598,363 and paid $430,997; for 20,106 services of 59 kinds; $18,971 of it was for drugs given in the office and $412,027 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,258 | 20,106 | 75 | 1.13 | $1,260,826 | $430,997 |
| 2023 | 1,171 | 14,903 | 75 | 1.11 | $857,756 | $419,496 |
| 2022 | 1,207 | 17,253 | 75 | 1.12 | $1,075,021 | $543,981 |
| 2021 | 1,094 | 16,925 | 74 | 1.11 | $886,329 | $515,967 |
| 2020 | 1,276 | 22,024 | 75 | 1.16 | $836,133 | $533,218 |
| 2019 | 1,664 | 21,419 | 75 | 1.22 | $837,529 | $536,237 |
| 2018 | 1,670 | 17,567 | 75 | 1.19 | $766,879 | $516,635 |
| 2017 | 1,786 | 11,527 | 74 | 1.22 | $800,630 | $536,780 |
| 2016 | 1,114 | 6,727 | 74 | 1.25 | $478,589 | $297,602 |
| 2015 | 1,106 | 6,689 | 74 | 1.25 | $522,502 | $333,837 |
| 2014 | 899 | 5,091 | 74 | 1.13 | $501,251 | $300,722 |
| 2013 | 823 | 4,920 | 74 | 1.31 | $462,422 | $296,004 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 30 services
| Short return visit (20+ min) | 719 | $93,729 | $76 |
| Treatment of inflammatory skin disease using laser, less than 250.0 sq cm | 16 | $38,753 | $164 |
| Treatment of inflammatory skin disease using laser, more than 500.0 sq cm | 12 | $35,758 | $242 |
| Destruction of skin growth, 1-14 growths | 187 | $28,659 | $107 |
| Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm | 15 | $26,124 | $178 |
| Return visit (30+ min) | 164 | $25,856 | $110 |
| Destruction of precancer skin growth, 1 growth | 261 | $22,141 | $57 |
| Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | 23 | $21,154 | $130 |
| New patient visit (30+ min) | 166 | $14,161 | $85 |
| Short return visit | 206 | $12,039 | $47 |
| Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | 45 | $11,940 | None |
| Destruction of precancer skin growth, 2-14 growths | 209 | $10,307 | $7 |
| Application of light by qualified health care professional to destroy precancer skin growth | 42 | $9,578 | $218 |
| Punch biopsy, first skin growth | 62 | $8,092 | $123 |
| Destruction of precancer skin growth, 15 or more growths | 34 | $7,024 | $167 |
| Biopsy of related skin growth, first growth | 63 | $6,913 | $95 |
| Injection into skin growth, 1-7 growths | 50 | $4,323 | $45 |
| New patient visit (45+ min) | 31 | $4,153 | $134 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 13 | $3,843 | $296 |
| Destruction of skin growth, 15 or more growths | 20 | $3,291 | $113 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 18 | $2,266 | $119 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 17 | $1,921 | $107 |
| New patient visit (15+ min) | 34 | $1,811 | $53 |
| Pathology examination of tissue using a microscope, intermediate complexity | 23 | $1,774 | $54 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | 11 | $1,358 | $123 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | 12 | $1,236 | $103 |
| Simple or single drainage of skin abscess | 11 | $1,222 | $111 |
| Biopsy of related skin growth, each additional growth | 11 | $793 | $53 |
| Pathology examination of tissue using a microscope, moderately low complexity | 13 | $623 | $39 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 58 | $117 | None |
2022: 28 services
| Short return visit (20+ min) | 767 | $96,462 | $78 |
| Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm | 17 | $39,179 | $181 |
| Treatment of inflammatory skin disease using laser, less than 250.0 sq cm | 21 | $35,434 | $163 |
| Destruction of skin growth, 1-14 growths | 222 | $33,844 | $109 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 43 | $24,498 | $521 |
| High dose rate electronic brachytherapy, external | 12 | $22,950 | $134 |
| Destruction of precancer skin growth, 1 growth | 285 | $22,774 | $56 |
| Short return visit | 310 | $20,125 | $48 |
| New patient visit (30+ min) | 198 | $17,110 | $86 |
| Return visit (30+ min) | 115 | $16,497 | $109 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 23 | $15,521 | $419 |
| Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | 21 | $14,318 | $128 |
| Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | 47 | $13,648 | None |
| Application of light by qualified health care professional to destroy precancer skin growth | 43 | $11,383 | $232 |
| Destruction of precancer skin growth, 2-14 growths | 237 | $11,001 | $7 |
| Punch biopsy, first skin growth | 68 | $9,511 | $130 |
| Biopsy of related skin growth, first growth | 89 | $9,125 | $97 |
| Destruction of precancer skin growth, 15 or more growths | 35 | $7,395 | $168 |
| Injection into skin growth, 1-7 growths | 62 | $5,358 | $47 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 16 | $5,210 | $306 |
| Destruction of skin growth, 15 or more growths | 28 | $4,386 | $107 |
| New patient visit (15+ min) | 50 | $3,012 | $60 |
| Pathology examination of tissue using a microscope, intermediate complexity | 28 | $2,741 | $69 |
| New patient visit (45+ min) | 15 | $2,152 | $143 |
| Simple or single drainage of skin abscess | 17 | $2,141 | $113 |
| Injection into skin growth, more than 7 growths | 13 | $1,063 | $56 |
| Biopsy of related skin growth, each additional growth | 11 | $691 | $53 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 76 | $161 | None |
2021: 31 services
| Short return visit (20+ min) | 676 | $86,609 | $76 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 69 | $38,220 | $531 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 44 | $34,459 | $415 |
| Destruction of skin growth, 1-14 growths | 188 | $30,546 | $111 |
| Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm | 14 | $28,534 | $188 |
| Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | 23 | $27,577 | $125 |
| Short return visit | 342 | $24,354 | $45 |
| Treatment of inflammatory skin disease using laser, less than 250.0 sq cm | 17 | $24,160 | $162 |
| New patient visit (30+ min) | 200 | $19,766 | $99 |
| Destruction of precancer skin growth, 1 growth | 239 | $18,773 | $54 |
| Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | 17 | $17,773 | $987 |
| Biopsy of related skin growth, first growth | 153 | $17,643 | $100 |
| Return visit (30+ min) | 91 | $13,979 | $103 |
| Application of light by qualified health care professional to destroy precancer skin growth | 52 | $13,651 | $235 |
| Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | 53 | $13,577 | None |
| Punch biopsy, first skin growth | 71 | $10,279 | $133 |
| Pathology examination of tissue using a microscope, intermediate complexity | 93 | $10,105 | $72 |
| Destruction of precancer skin growth, 2-14 growths | 195 | $8,793 | $6 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 20 | $7,384 | $308 |
| Injection into skin growth, 1-7 growths | 60 | $6,313 | $51 |
| Destruction of precancer skin growth, 15 or more growths | 31 | $6,235 | $160 |
| Destruction of skin growth, 15 or more growths | 21 | $4,343 | $132 |
| Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less | 14 | $4,338 | $289 |
| New patient visit (15+ min) | 55 | $3,564 | $65 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | 11 | $2,945 | $268 |
| Simple or single drainage of skin abscess | 16 | $2,016 | $126 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 12 | $1,399 | $117 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | 12 | $1,181 | $98 |
| Biopsy of related skin growth, each additional growth | 13 | $718 | $55 |
| Pathology examination of tissue using a microscope, moderately low complexity | 12 | $617 | $44 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 64 | $201 | None |
2020: 29 services
| Short return visit (20+ min) | 558 | $54,359 | $65 |
| Short return visit | 670 | $49,609 | $40 |
| Treatment of inflammatory skin disease using laser, less than 250.0 sq cm | 22 | $40,993 | $167 |
| Destruction of skin growth, 1-14 growths | 246 | $37,213 | $108 |
| Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm | 19 | $30,444 | $186 |
| Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | 25 | $28,633 | $123 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 28 | $28,140 | $408 |
| Destruction of precancer skin growth, 1 growth | 347 | $26,446 | $53 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 37 | $20,715 | $482 |
| Biopsy of related skin growth, first growth | 174 | $19,551 | $95 |
| Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | 65 | $16,383 | None |
| Pathology examination of tissue using a microscope, intermediate complexity | 155 | $16,307 | $69 |
| Application of light by qualified health care professional to destroy precancer skin growth | 61 | $16,035 | $226 |
| Treatment of inflammatory skin disease using laser, more than 500.0 sq cm | 12 | $15,783 | $247 |
| Destruction of precancer skin growth, 2-14 growths | 286 | $12,603 | $6 |
| Destruction of precancer skin growth, 15 or more growths | 54 | $9,691 | $154 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 30 | $9,201 | $297 |
| Punch biopsy, first skin growth | 64 | $8,547 | $124 |
| New patient visit (15+ min) | 157 | $8,470 | $54 |
| New patient visit (30+ min) | 91 | $8,279 | $91 |
| Injection into skin growth, 1-7 growths | 80 | $6,333 | $45 |
| Return visit (30+ min) | 51 | $6,210 | $94 |
| Destruction of skin growth, 15 or more growths | 23 | $4,944 | $121 |
| Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less | 17 | $4,943 | $275 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | 17 | $4,489 | $249 |
| Simple or single drainage of skin abscess | 25 | $2,942 | $113 |
| Biopsy of related skin growth, each additional growth | 17 | $1,036 | $55 |
| Pathology examination of tissue using a microscope, moderately low complexity | 11 | $471 | $43 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 87 | $193 | None |
2019: 33 services
| Short return visit | 1,009 | $74,263 | $40 |
| Short return visit (20+ min) | 703 | $69,347 | $66 |
| Destruction of skin growth, 1-14 growths | 300 | $51,090 | $108 |
| Destruction of precancer skin growth, 1 growth | 471 | $39,172 | $58 |
| Treatment of inflammatory skin disease using laser, more than 500.0 sq cm | 11 | $27,977 | $233 |
| Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm | 11 | $26,753 | $180 |
| Biopsy of related skin growth, first growth | 216 | $23,254 | $93 |
| Pathology examination of tissue using a microscope, intermediate complexity | 206 | $20,863 | $66 |
| New patient visit (15+ min) | 316 | $20,767 | $66 |
| Treatment of inflammatory skin disease using laser, less than 250.0 sq cm | 20 | $19,129 | $156 |
| Destruction of precancer skin growth, 2-14 growths | 394 | $15,618 | $5 |
| Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | 21 | $15,348 | $94 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 42 | $14,035 | $292 |
| Punch biopsy, first skin growth | 104 | $13,749 | $125 |
| Destruction of precancer skin growth, 15 or more growths | 68 | $13,203 | $140 |
| Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | 67 | $12,664 | None |
| New patient visit (30+ min) | 100 | $9,930 | $99 |
| Injection into skin growth, 1-7 growths | 79 | $6,752 | $48 |
| Application of light to destroy precancer skin growth | 45 | $5,901 | $126 |
| Destruction of skin growth, 15 or more growths | 27 | $5,109 | $128 |
| Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm | 16 | $4,278 | $267 |
| Return visit (30+ min) | 35 | $4,127 | $98 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 24 | $3,668 | $126 |
| Application of light with debridement to destroy precancer skin growth | 11 | $3,477 | $267 |
| Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less | 12 | $2,798 | $233 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | 11 | $2,573 | $234 |
| Application of light by qualified health care professional to destroy precancer skin growth | 12 | $2,485 | $207 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 16 | $2,171 | $136 |
| Simple or single drainage of skin abscess | 16 | $1,752 | $97 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 11 | $1,747 | $146 |
| Application of ultraviolet light to skin | 11 | $1,583 | $22 |
| Biopsy of related skin growth, each additional growth | 26 | $1,347 | $52 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 85 | $233 | None |
2018: 32 services
| Short return visit | 1,018 | $68,823 | $37 |
| Short return visit (20+ min) | 672 | $58,855 | $59 |
| Destruction of skin growth, 1-14 growths | 292 | $46,882 | $101 |
| Destruction of precancer skin growth, 1 growth | 485 | $40,386 | $53 |
| Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm | 15 | $37,656 | $169 |
| Treatment of inflammatory skin disease using laser, less than 250.0 sq cm | 25 | $32,895 | $144 |
| Biopsy of single growth of skin and/or tissue | 302 | $32,011 | $94 |
| Treatment of inflammatory skin disease using laser, more than 500.0 sq cm | 14 | $30,646 | $229 |
| Pathology examination of tissue using a microscope, intermediate complexity | 216 | $19,582 | $64 |
| New patient visit (15+ min) | 314 | $18,219 | $58 |
| Destruction of precancer skin growth, 2-14 growths | 428 | $17,816 | $5 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 39 | $12,100 | $288 |
| Destruction of precancer skin growth, 15 or more growths | 74 | $12,052 | $128 |
| New patient visit (30+ min) | 116 | $10,519 | $91 |
| Injection into skin growth, 1-7 growths | 90 | $8,194 | $47 |
| Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | 18 | $8,044 | $72 |
| Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | 42 | $7,483 | None |
| Application of ultraviolet light to skin | 22 | $4,165 | $18 |
| Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm | 14 | $3,726 | $266 |
| Destruction of skin growth, 15 or more growths | 18 | $3,536 | $118 |
| Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less | 16 | $3,478 | $217 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | 14 | $3,262 | $217 |
| Intermediate repair of wound of neck, hands, feet, or genitals, 2.6-7.5 cm | 13 | $3,124 | $240 |
| Application of light to destroy precancer skin growth | 26 | $3,058 | $105 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 20 | $2,571 | $112 |
| Application of light by qualified health care professional to destroy precancer skin growth | 13 | $2,377 | $183 |
| Simple or single drainage of skin abscess | 21 | $2,216 | $106 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 14 | $1,962 | $140 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 12 | $1,858 | $143 |
| Biopsy of each additional growth of skin and/or tissue | 22 | $674 | $29 |
| Pathology examination of tissue using a microscope, moderately low complexity | 12 | $482 | $40 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 98 | $326 | None |
2017: 28 services
| Short return visit (20+ min) | 741 | $61,638 | $58 |
| Short return visit | 995 | $60,083 | $35 |
| Treatment of inflammatory skin disease using laser, more than 500.0 sq cm | 19 | $44,748 | $223 |
| Destruction of skin growth, 1-14 growths | 303 | $44,748 | $99 |
| Destruction of precancer skin growth, 1 growth | 543 | $43,094 | $52 |
| Biopsy of single growth of skin and/or tissue | 354 | $37,783 | $90 |
| Treatment of inflammatory skin disease using laser, less than 250.0 sq cm | 22 | $36,953 | $143 |
| Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm | 19 | $25,741 | $160 |
| Pathology examination of tissue using a microscope, intermediate complexity | 252 | $23,553 | $63 |
| New patient visit (15+ min) | 345 | $19,072 | $55 |
| Destruction of precancer skin growth, 2-14 growths | 476 | $18,711 | $5 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 51 | $15,571 | None |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 47 | $13,715 | $269 |
| Destruction of precancer skin growth, 15 or more growths | 81 | $13,610 | $131 |
| New patient visit (30+ min) | 145 | $12,093 | $83 |
| Application of ultraviolet light to skin | 26 | $8,382 | $20 |
| Application of light to destroy precancer skin growth | 51 | $6,856 | $122 |
| Injection into skin growth, 1-7 growths | 80 | $6,809 | $44 |
| Destruction of skin growth, 15 or more growths | 14 | $3,591 | $109 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 30 | $3,555 | $111 |
| Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm | 12 | $3,222 | $269 |
| Simple or single drainage of skin abscess | 18 | $2,003 | $100 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 12 | $1,617 | $135 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 11 | $1,073 | $98 |
| Biopsy of each additional growth of skin and/or tissue | 34 | $1,003 | $28 |
| Pathology examination of tissue using a microscope, moderately low complexity | 16 | $635 | $37 |
| Injection of drug or substance under skin or into muscle | 15 | $491 | $25 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 94 | $339 | None |
2016: 21 services
| Short return visit | 673 | $41,216 | $36 |
| Short return visit (20+ min) | 388 | $31,837 | $59 |
| Destruction of precancer skin growth, 1 growth | 326 | $26,280 | $53 |
| Treatment of inflammatory skin disease using laser, less than 250.0 sq cm | 13 | $24,601 | $146 |
| Destruction of skin growth, 1-14 growths | 160 | $21,918 | $100 |
| Biopsy of single growth of skin and/or tissue | 164 | $16,668 | $92 |
| Pathology examination of tissue using a microscope, intermediate complexity | 124 | $12,070 | $68 |
| New patient visit (15+ min) | 205 | $11,959 | $58 |
| Destruction of precancer skin growth, 2-14 growths | 281 | $11,268 | $5 |
| Application of ultraviolet light to skin | 17 | $7,971 | $20 |
| New patient visit (30+ min) | 91 | $7,473 | $82 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 18 | $5,990 | $272 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 20 | $5,552 | None |
| Injection into skin growth, 1-7 growths | 69 | $5,240 | $46 |
| Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less | 14 | $3,332 | $238 |
| Destruction of skin growth, 15 or more growths | 15 | $3,267 | $113 |
| Application of light to destroy precancer skin growth | 20 | $2,803 | $117 |
| Destruction of precancer skin growth, 15 or more growths | 20 | $2,709 | $129 |
| Simple or single drainage of skin abscess | 23 | $2,476 | $103 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | 11 | $2,417 | $220 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 74 | $158 | None |
2015: 22 services
| Short return visit | 680 | $50,119 | $39 |
| Treatment of inflammatory skin disease using laser, more than 500.0 sq cm | 11 | $34,035 | $227 |
| Destruction of skin growth, 1-14 growths | 202 | $30,914 | $104 |
| Destruction of precancer skin growth, 1 growth | 306 | $26,752 | $57 |
| Short return visit (20+ min) | 302 | $26,106 | $63 |
| Biopsy of single growth of skin and/or tissue | 166 | $17,573 | $95 |
| New patient visit (30+ min) | 149 | $13,475 | $90 |
| New patient visit (15+ min) | 199 | $12,705 | $64 |
| Pathology examination of tissue using a microscope, intermediate complexity | 124 | $12,405 | $69 |
| Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm | 11 | $11,951 | $166 |
| Destruction of precancer skin growth, 2-14 growths | 258 | $10,895 | $5 |
| Application of ultraviolet light to skin | 20 | $8,990 | $20 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 17 | $5,419 | $285 |
| Injection into skin growth, 1-7 growths | 66 | $5,256 | $48 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 21 | $4,378 | None |
| Destruction of precancer skin growth, 15 or more growths | 24 | $3,860 | $138 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | 16 | $3,709 | $218 |
| Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less | 15 | $3,551 | $222 |
| Application of light to destroy precancer skin growth | 20 | $2,735 | $124 |
| Destruction of skin growth, 15 or more growths | 17 | $2,637 | $120 |
| Simple or single drainage of skin abscess | 13 | $1,249 | $96 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 69 | $147 | None |
2014: 22 services
| Treatment of inflammatory skin disease using laser, more than 500.0 sq cm | 17 | $72,095 | $225 |
| Short return visit | 596 | $41,532 | $38 |
| Destruction of precancer skin growth, 1 growth | 239 | $23,577 | $66 |
| Destruction of skin growth, 1-14 growths | 150 | $21,775 | $101 |
| Short return visit (20+ min) | 189 | $16,932 | $62 |
| Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm | 14 | $15,673 | $160 |
| Biopsy of single growth of skin and/or tissue | 139 | $14,006 | $93 |
| Destruction of precancer skin growth, 2-14 growths | 204 | $12,817 | $9 |
| New patient visit (15+ min) | 145 | $9,185 | $63 |
| Pathology examination of tissue using a microscope, intermediate complexity | 97 | $8,938 | $66 |
| New patient visit (30+ min) | 79 | $7,375 | $93 |
| Injection into skin growth, 1-7 growths | 74 | $5,761 | $48 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 17 | $5,026 | $279 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 25 | $4,417 | None |
| Application of ultraviolet light to skin | 19 | $4,408 | $20 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | 15 | $3,115 | $208 |
| Application of light to destroy precancer skin growth | 25 | $2,857 | $114 |
| Destruction of skin growth, 15 or more growths | 11 | $2,246 | $125 |
| Destruction of precancer skin growth, 15 or more growths | 14 | $1,880 | $134 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 12 | $1,472 | $123 |
| Pathology examination of tissue using a microscope, moderately low complexity | 15 | $674 | $42 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 82 | $171 | None |
2013: 24 services
| Treatment of inflammatory skin disease using laser, more than 500.0 sq cm | 11 | $50,389 | $234 |
| Short return visit | 577 | $47,856 | $40 |
| Destruction of precancer skin growth, 1 growth | 196 | $23,721 | $76 |
| Treatment of inflammatory skin disease using laser, less than 250.0 sq cm | 12 | $20,067 | $154 |
| Destruction of skin growth, 1-14 growths | 124 | $19,144 | $109 |
| Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm | 13 | $19,104 | $169 |
| Short return visit (20+ min) | 191 | $18,267 | $64 |
| Biopsy of single growth of skin and/or tissue | 120 | $13,090 | $100 |
| New patient visit (15+ min) | 156 | $10,386 | $67 |
| Pathology examination of tissue using a microscope, intermediate complexity | 78 | $7,888 | $67 |
| Destruction of precancer skin growth, 2-14 growths | 162 | $7,871 | $6 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 22 | $6,448 | $293 |
| Injection into skin growth, 1-7 growths | 63 | $5,318 | $50 |
| Application of ultraviolet light to skin | 17 | $4,852 | $22 |
| New patient visit (30+ min) | 50 | $4,688 | $94 |
| Destruction of skin growth, 15 or more growths | 11 | $3,966 | $132 |
| Application of light to destroy precancer skin growth | 17 | $2,705 | $142 |
| Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less | 11 | $2,483 | $226 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 17 | $2,439 | None |
| Simple or single drainage of skin abscess | 15 | $1,768 | $111 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 14 | $1,650 | $118 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day at least 10 minutes | 15 | $1,027 | $38 |
| Pathology examination of tissue using a microscope, moderately low complexity | 13 | $609 | $43 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 67 | $153 | None |
Medicaid work
$195,567 in 2024
Medicaid paid $195,567 for 4,505 billed services this clinician did in 2024, up to 167 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 1,736 | $69,054 |
| Return visit (30+ min) | 903 | $54,439 |
| New patient visit (30+ min) | 562 | $26,939 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 290 | $15,862 |
| New patient visit (45+ min) | 83 | $6,523 |
| Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B | 102 | $5,208 |
| Injection, intralesional; up to and including 7 lesions | 177 | $5,147 |
| Short return visit | 145 | $4,638 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 66 | $2,703 |
| Excimer laser treatment for psoriasis; total area less than 250 sq cm | 30 | $2,177 |
| Punch biopsy of skin (including simple closure, when performed); single lesion | 12 | $1,066 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 359 | $824 |
| 2024 | 4,505 | 14 | 167 | $195,567 |
| 2023 | 4,823 | 13 | 172 | $247,881 |
| 2022 | 3,378 | 11 | 177 | $191,376 |
| 2021 | 3,142 | 9 | 134 | $212,362 |
| 2020 | 2,348 | 6 | 110 | $154,453 |
| 2019 | 2,951 | 8 | 157 | $210,977 |
| 2018 | 2,533 | 9 | 114 | $181,751 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 1,370 | $57,994 |
| Return visit (30+ min) | 901 | $53,727 |
| Excimer laser treatment for psoriasis; total area less than 250 sq cm | 406 | $45,703 |
| New patient visit (30+ min) | 605 | $35,736 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 248 | $16,692 |
| Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B | 162 | $11,237 |
| New patient visit (45+ min) | 128 | $10,908 |
| Injection, intralesional; up to and including 7 lesions | 296 | $6,678 |
| Short return visit | 169 | $5,067 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 63 | $1,597 |
| Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion | 26 | $1,371 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 419 | $827 |
2022
| Short return visit (20+ min) | 1,364 | $84,100 |
| New patient visit (30+ min) | 586 | $34,368 |
| Return visit (30+ min) | 439 | $31,022 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 193 | $14,756 |
| Injection, intralesional; up to and including 7 lesions | 244 | $9,129 |
| Short return visit | 149 | $6,570 |
| New patient visit (45+ min) | 61 | $5,492 |
| Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B | 27 | $2,967 |
| Punch biopsy of skin (including simple closure, when performed); single lesion | 12 | $1,126 |
| Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion | 17 | $1,046 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 286 | $800 |
2021
| Short return visit (20+ min) | 1,328 | $99,019 |
| New patient visit (30+ min) | 711 | $50,165 |
| Return visit (30+ min) | 392 | $35,741 |
| Injection, intralesional; up to and including 7 lesions | 231 | $9,306 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 89 | $8,805 |
| Short return visit | 90 | $5,271 |
| Punch biopsy of skin (including simple closure, when performed); single lesion | 25 | $1,795 |
| Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion | 16 | $1,420 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 260 | $840 |
2020
| Short return visit (20+ min) | 789 | $55,014 |
| New patient visit (30+ min) | 461 | $49,467 |
| Short return visit | 712 | $34,269 |
| Injection, intralesional; up to and including 7 lesions | 136 | $8,217 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 67 | $6,659 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 183 | $828 |
2019
| Short return visit | 1,196 | $57,825 |
| New patient visit (30+ min) | 494 | $46,569 |
| Short return visit (20+ min) | 567 | $38,770 |
| Excimer laser treatment for psoriasis; over 500 sq cm | 106 | $25,124 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 164 | $20,328 |
| Injection, intralesional; up to and including 7 lesions | 178 | $11,441 |
| Excimer laser treatment for psoriasis; 250 sq cm to 500 sq cm | 40 | $10,022 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 206 | $898 |
2018
| Short return visit | 1,099 | $56,232 |
| New patient visit (30+ min) | 372 | $44,675 |
| Short return visit (20+ min) | 386 | $28,278 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 202 | $27,866 |
| Injection, intralesional; up to and including 7 lesions | 215 | $15,613 |
| Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B | 40 | $3,997 |
| Service | 25 | $3,168 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 182 | $987 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 12 | $933 |
Drugs they prescribed that Part D paid
$594,121
Pharmacies billed $594,121 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,222) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
2,088 generic and 134 brand-name prescriptions · $594,121 in drug cost · 83 antibiotic prescriptions to 39 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Enbrel Sureclick | 17 | $150,823 | $8,872 |
| Otezla | 13 | $53,421 | $4,109 |
| Betamethasone Dipropionate | 183 | $10,822 | $59 |
| Calcipotriene | 60 | $8,382 | $140 |
| Tacrolimus | 60 | $8,084 | $135 |
See all 35 drugs
| Enbrel Sureclick | 17 | $150,823 | $8,872 |
| Otezla | 13 | $53,421 | $4,109 |
| Betamethasone Dipropionate | 183 | $10,822 | $59 |
| Calcipotriene | 60 | $8,382 | $140 |
| Tacrolimus | 60 | $8,084 | $135 |
| Fluocinonide | 175 | $7,287 | $42 |
| Ketoconazole | 192 | $4,309 | $22 |
| Fluorouracil | 47 | $3,315 | $71 |
| Doxycycline Hyclate | 39 | $2,927 | $75 |
| Clindamycin Phosphate | 84 | $2,703 | $32 |
| Desonide | 50 | $2,366 | $47 |
| Mometasone Furoate | 107 | $2,112 | $20 |
| Triamcinolone Acetonide | 185 | $2,021 | $11 |
| Azelaic Acid | 24 | $2,001 | $83 |
| Metronidazole | 29 | $1,604 | $55 |
| Tretinoin | 29 | $1,486 | $51 |
| Hydrocortisone | 251 | $1,452 | $6 |
| Clobetasol Propionate | 17 | $1,308 | $77 |
| Adapalene | 12 | $1,114 | $93 |
| Econazole Nitrate | 36 | $1,025 | $28 |
| Valacyclovir | 23 | $987 | $43 |
| Betamethasone Diprop Augmented | 18 | $986 | $55 |
| Selenium Sulfide | 58 | $830 | $14 |
| Ciclopirox | 34 | $812 | $24 |
| Hydroxyzine | 111 | $788 | $7 |
| Fluticasone Propionate | 18 | $714 | $40 |
| Mupirocin | 68 | $483 | $7 |
| Doxycycline Monohydrate | 21 | $374 | $18 |
| Spironolactone | 17 | $351 | $21 |
| Imiquimod | 17 | $279 | $16 |
| Minoxidil | 30 | $181 | $6 |
| Terbinafine | 13 | $122 | $9 |
| Cephalexin | 11 | $63 | $6 |
| Prednisone | 11 | $36 | $3 |
| Hydroxychloroquine Sulfate | 12 | $12 | $1 |
Year by year
| 2024 | 2,222 | 641 | 0% (0) | 6% | $594,121 |
| 2023 | 2,139 | 660 | None | None | $585,516 |
| 2022 | 2,069 | 660 | None | 10% | $910,814 |
| 2021 | 1,980 | 596 | None | 12% | $606,478 |
| 2020 | 2,077 | 587 | None | 11% | $462,416 |
| 2019 | 2,106 | 670 | None | 11% | $377,572 |
| 2018 | 1,979 | 642 | 0% (0) | None | $414,729 |
| 2017 | 2,250 | 742 | None | None | $352,437 |
| 2016 | 2,319 | 697 | None | None | $305,931 |
| 2015 | 2,248 | 624 | None | None | $318,192 |
| 2014 | 2,093 | 593 | None | None | $246,269 |
| 2013 | 2,251 | 592 | 0% (0) | None | $192,990 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 34 drugs
| Enbrel Sureclick | 11 | $116,289 | $10,572 |
| Otezla | 17 | $79,307 | $4,665 |
| Betamethasone Dipropionate | 177 | $14,067 | $79 |
| Tacrolimus | 52 | $13,262 | $255 |
| Calcipotriene | 53 | $12,178 | $230 |
| Fluocinonide | 219 | $11,951 | $55 |
| Calcipotriene-Betamethasone | 13 | $7,658 | $589 |
| Clindamycin Phosphate | 118 | $6,165 | $52 |
| Ketoconazole | 159 | $4,583 | $29 |
| Fluorouracil | 33 | $4,405 | $133 |
| Metronidazole | 33 | $3,889 | $118 |
| Tretinoin | 44 | $3,377 | $77 |
| Clobetasol Propionate | 27 | $2,862 | $106 |
| Mometasone Furoate | 113 | $2,707 | $24 |
| Triamcinolone Acetonide | 182 | $2,504 | $14 |
| Desonide | 28 | $2,334 | $83 |
| Econazole Nitrate | 34 | $1,666 | $49 |
| Fluocinolone Acetonide | 24 | $1,603 | $67 |
| Hydrocortisone | 220 | $1,575 | $7 |
| Doxycycline Hyclate | 28 | $1,490 | $53 |
| Valacyclovir | 29 | $1,171 | $40 |
| Selenium Sulfide | 60 | $1,091 | $18 |
| Doxycycline Monohydrate | 24 | $982 | $41 |
| Hydroxyzine | 71 | $959 | $14 |
| Ciclopirox | 17 | $867 | $51 |
| Betamethasone Diprop Augmented | 19 | $789 | $42 |
| Clotrimazole | 22 | $689 | $31 |
| Mupirocin | 61 | $614 | $10 |
| Fluticasone Propionate | 16 | $413 | $26 |
| Imiquimod | 17 | $284 | $17 |
| Minocycline | 12 | $245 | $20 |
| Gabapentin | 12 | $238 | $20 |
| Minoxidil | 19 | $172 | $9 |
| Prednisone | 13 | $41 | $3 |
2022: 34 drugs
| Enbrel Sureclick | 32 | $274,589 | $8,581 |
| Otezla | 37 | $162,325 | $4,387 |
| Enbrel Mini | 15 | $103,722 | $6,915 |
| Cosentyx Pen (2 Pens) | 11 | $71,724 | $6,520 |
| Dupixent | 12 | $43,702 | $3,642 |
| Fluocinonide | 282 | $20,216 | $72 |
| Betamethasone Dipropionate | 158 | $14,584 | $92 |
| Tacrolimus | 46 | $12,443 | $270 |
| Calcipotriene | 56 | $10,509 | $188 |
| Ketoconazole | 166 | $4,853 | $29 |
| Clindamycin Phosphate | 66 | $4,033 | $61 |
| Fluorouracil | 34 | $3,477 | $102 |
| Clobetasol Propionate | 40 | $2,784 | $70 |
| Desonide | 30 | $2,583 | $86 |
| Tretinoin | 45 | $2,547 | $57 |
| Triamcinolone Acetonide | 165 | $2,538 | $15 |
| Metronidazole | 31 | $2,425 | $78 |
| Econazole Nitrate | 39 | $1,826 | $47 |
| Mometasone Furoate | 54 | $1,807 | $33 |
| Hydroxyzine | 104 | $1,229 | $12 |
| Doxycycline Hyclate | 31 | $1,158 | $37 |
| Fluocinolone Acetonide | 16 | $1,136 | $71 |
| Hydrocortisone | 135 | $1,090 | $8 |
| Betamethasone Diprop Augmented | 22 | $1,005 | $46 |
| Ciclopirox | 25 | $994 | $40 |
| Mupirocin | 80 | $852 | $11 |
| Selenium Sulfide | 45 | $571 | $13 |
| Fluticasone Propionate | 14 | $496 | $35 |
| Clotrimazole | 19 | $431 | $23 |
| Doxycycline Monohydrate | 14 | $414 | $30 |
| Valacyclovir | 13 | $414 | $32 |
| Cephalexin | 19 | $165 | $9 |
| Terbinafine | 15 | $148 | $10 |
| Prednisone | 11 | $71 | $6 |
2021: 33 drugs
| Enbrel Sureclick | 19 | $157,047 | $8,266 |
| Otezla | 20 | $81,676 | $4,084 |
| Cosentyx Pen (2 Pens) | 13 | $76,248 | $5,865 |
| Dupixent | 14 | $47,367 | $3,383 |
| Fluocinonide | 291 | $20,664 | $71 |
| Enstilar | 12 | $15,156 | $1,263 |
| Calcipotriene-Betamethasone Dp | 12 | $12,484 | $1,040 |
| Betamethasone Dipropionate | 155 | $11,106 | $72 |
| Tacrolimus | 43 | $8,642 | $201 |
| Pimecrolimus | 12 | $7,390 | $616 |
| Calcipotriene | 38 | $6,472 | $170 |
| Ketoconazole | 132 | $4,174 | $32 |
| Tretinoin | 49 | $3,422 | $70 |
| Fluorouracil | 32 | $3,415 | $107 |
| Metronidazole | 38 | $3,340 | $88 |
| Clindamycin Phosphate | 57 | $3,177 | $56 |
| Clobetasol Propionate | 57 | $3,058 | $54 |
| Desonide | 32 | $2,786 | $87 |
| Triamcinolone Acetonide | 174 | $2,727 | $16 |
| Betamethasone Diprop Augmented | 24 | $1,845 | $77 |
| Doxycycline Hyclate | 40 | $1,282 | $32 |
| Mometasone Furoate | 38 | $1,073 | $28 |
| Hydrocortisone | 132 | $936 | $7 |
| Ciclopirox | 30 | $881 | $29 |
| Mupirocin | 72 | $861 | $12 |
| Selenium Sulfide | 75 | $842 | $11 |
| Econazole Nitrate | 22 | $784 | $36 |
| Hydroxyzine | 72 | $674 | $9 |
| Clotrimazole | 24 | $601 | $25 |
| Doxycycline Monohydrate | 17 | $398 | $23 |
| Cephalexin | 24 | $147 | $6 |
| Gabapentin | 11 | $125 | $11 |
| Prednisone | 12 | $108 | $9 |
2020: 32 drugs
| Enbrel Sureclick | 17 | $102,309 | $6,018 |
| Dupixent | 19 | $61,207 | $3,221 |
| Otezla | 11 | $41,062 | $3,733 |
| Fluocinonide | 344 | $23,204 | $67 |
| Calcipotriene | 59 | $11,754 | $199 |
| Betamethasone Dipropionate | 119 | $8,266 | $69 |
| Pimecrolimus | 14 | $7,612 | $544 |
| Ketoconazole | 176 | $6,278 | $36 |
| Fluorouracil | 39 | $6,095 | $156 |
| Tacrolimus | 20 | $5,039 | $252 |
| Clindamycin Phosphate | 50 | $3,488 | $70 |
| Tretinoin | 58 | $3,170 | $55 |
| Triamcinolone Acetonide | 195 | $3,017 | $15 |
| Metronidazole | 33 | $2,928 | $89 |
| Clobetasol Propionate | 54 | $2,847 | $53 |
| Desonide | 30 | $2,253 | $75 |
| Betamethasone Diprop Augmented | 26 | $2,237 | $86 |
| Doxycycline Hyclate | 56 | $1,838 | $33 |
| Fluocinolone Acetonide | 20 | $1,509 | $75 |
| Econazole Nitrate | 40 | $1,452 | $36 |
| Ciclopirox | 37 | $1,050 | $28 |
| Hydrocortisone | 134 | $930 | $7 |
| Selenium Sulfide | 75 | $896 | $12 |
| Clotrimazole | 46 | $846 | $18 |
| Hydroxyzine | 65 | $750 | $12 |
| Fluticasone Propionate | 17 | $658 | $39 |
| Mupirocin | 72 | $599 | $8 |
| Doxycycline Monohydrate | 14 | $481 | $34 |
| Minocycline | 12 | $457 | $38 |
| Mometasone Furoate | 20 | $426 | $21 |
| Valacyclovir | 12 | $356 | $30 |
| Cephalexin | 24 | $86 | $4 |
2019: 32 drugs
| Enbrel Sureclick | 15 | $75,140 | $5,009 |
| Otezla | 17 | $59,177 | $3,481 |
| Fluocinonide | 370 | $22,736 | $61 |
| Calcipotriene | 51 | $11,869 | $233 |
| Tacrolimus | 18 | $7,051 | $392 |
| Betamethasone Dipropionate | 105 | $7,004 | $67 |
| Clindamycin Phosphate | 84 | $6,480 | $77 |
| Ketoconazole | 170 | $5,751 | $34 |
| Fluorouracil | 39 | $5,476 | $140 |
| Clobetasol Propionate | 53 | $4,918 | $93 |
| Metronidazole | 39 | $3,801 | $97 |
| Econazole Nitrate | 55 | $3,619 | $66 |
| Desonide | 33 | $2,956 | $90 |
| Tretinoin | 35 | $2,939 | $84 |
| Triamcinolone Acetonide | 252 | $2,912 | $12 |
| Imiquimod | 24 | $2,253 | $94 |
| Betamethasone Diprop Augmented | 26 | $1,537 | $59 |
| Fluocinolone Acetonide | 15 | $1,417 | $94 |
| Ciclopirox | 37 | $1,244 | $34 |
| Doxycycline Hyclate | 22 | $1,221 | $56 |
| Hydrocortisone | 153 | $1,107 | $7 |
| Doxycycline Monohydrate | 27 | $1,062 | $39 |
| Selenium Sulfide | 78 | $916 | $12 |
| Clotrimazole | 42 | $850 | $20 |
| Mupirocin | 63 | $668 | $11 |
| Fluticasone Propionate | 18 | $625 | $35 |
| Hydroxyzine | 50 | $545 | $11 |
| Valacyclovir | 11 | $413 | $38 |
| Mometasone Furoate | 20 | $409 | $20 |
| Minocycline | 15 | $308 | $21 |
| Cephalexin | 15 | $229 | $15 |
| Gabapentin | 11 | $73 | $7 |
2018: 30 drugs
| Enbrel Sureclick | 18 | $103,759 | $5,764 |
| Otezla | 29 | $96,483 | $3,327 |
| Fluocinonide | 374 | $27,336 | $73 |
| Calcipotriene | 39 | $15,917 | $408 |
| Clobetasol Propionate | 89 | $11,600 | $130 |
| Econazole Nitrate | 60 | $6,819 | $114 |
| Fluorouracil | 46 | $6,543 | $142 |
| Desonide | 46 | $6,500 | $141 |
| Clindamycin Phosphate | 73 | $6,443 | $88 |
| Ketoconazole | 133 | $5,382 | $40 |
| Betamethasone Dipropionate | 74 | $5,185 | $70 |
| Tacrolimus | 15 | $4,219 | $281 |
| Triamcinolone Acetonide | 203 | $2,969 | $15 |
| Tretinoin | 21 | $2,636 | $126 |
| Metronidazole | 24 | $2,473 | $103 |
| Hydrocortisone | 204 | $1,642 | $8 |
| Betamethasone Diprop Augmented | 15 | $1,518 | $101 |
| Fluocinolone Acetonide | 16 | $1,420 | $89 |
| Doxycycline Hyclate | 16 | $1,042 | $65 |
| Clotrimazole | 34 | $964 | $28 |
| Selenium Sulfide | 69 | $691 | $10 |
| Hydroxyzine | 40 | $670 | $17 |
| Imiquimod | 12 | $649 | $54 |
| Ciclopirox | 24 | $588 | $25 |
| Doxycycline Monohydrate | 28 | $588 | $21 |
| Fluticasone Propionate | 18 | $504 | $28 |
| Mupirocin | 41 | $460 | $11 |
| Minocycline | 11 | $395 | $36 |
| Cephalexin | 18 | $250 | $14 |
| Mometasone Furoate | 11 | $218 | $20 |
2017: 31 drugs
| Cosentyx Pen (2 Pens) | 14 | $55,448 | $3,961 |
| Fluocinonide | 480 | $41,017 | $85 |
| Otezla | 13 | $38,686 | $2,976 |
| Clobetasol Propionate | 126 | $18,663 | $148 |
| Calcipotriene | 47 | $17,864 | $380 |
| Econazole Nitrate | 65 | $11,069 | $170 |
| Clindamycin Phosphate | 97 | $8,039 | $83 |
| Desonide | 44 | $6,575 | $149 |
| Betamethasone Dipropionate | 73 | $6,540 | $90 |
| Ketoconazole | 133 | $6,345 | $48 |
| Metronidazole | 46 | $6,205 | $135 |
| Fluorouracil | 23 | $3,274 | $142 |
| Triamcinolone Acetonide | 215 | $3,155 | $15 |
| Betamethasone Dipropionate | 16 | $2,661 | $166 |
| Tretinoin | 32 | $2,588 | $81 |
| Doxycycline Hyclate | 56 | $2,319 | $41 |
| Fluocinolone Acetonide | 17 | $2,175 | $128 |
| Hydrocortisone | 185 | $1,561 | $8 |
| Minocycline | 46 | $1,366 | $30 |
| Selenium Sulfide | 87 | $1,312 | $15 |
| Fluocinonide-E | 11 | $1,246 | $113 |
| Clotrimazole | 45 | $1,140 | $25 |
| Imiquimod | 13 | $1,127 | $87 |
| Alclometasone Dipropionate | 11 | $990 | $90 |
| Hydroxyzine | 33 | $710 | $22 |
| Doxycycline Monohydrate | 28 | $548 | $20 |
| Mupirocin | 60 | $539 | $9 |
| Methotrexate | 11 | $507 | $46 |
| Ciclopirox | 13 | $408 | $31 |
| Levocetirizine Dihydrochloride | 18 | $263 | $15 |
| Cephalexin | 12 | $78 | $6 |
2016: 31 drugs
| Fluocinonide | 535 | $49,598 | $93 |
| Clobetasol Propionate | 187 | $32,018 | $171 |
| Econazole Nitrate | 105 | $22,890 | $218 |
| Acitretin | 16 | $17,272 | $1,080 |
| Desonide | 96 | $16,064 | $167 |
| Calcipotriene | 26 | $10,702 | $412 |
| Fluorouracil | 29 | $7,008 | $242 |
| Ketoconazole | 122 | $5,851 | $48 |
| Betamethasone Dipropionate | 79 | $5,529 | $70 |
| Clindamycin Phosphate | 63 | $4,950 | $79 |
| Finacea | 15 | $4,133 | $276 |
| Triamcinolone Acetonide | 186 | $3,428 | $18 |
| Metronidazole | 26 | $3,265 | $126 |
| Doxycycline Hyclate | 65 | $3,076 | $47 |
| Tretinoin | 33 | $2,715 | $82 |
| Fluocinolone Acetonide | 22 | $1,999 | $91 |
| Selenium Sulfide | 71 | $1,295 | $18 |
| Permethrin | 13 | $1,267 | $97 |
| Minocycline | 34 | $805 | $24 |
| Hydrocortisone | 108 | $752 | $7 |
| Doxycycline Monohydrate | 37 | $742 | $20 |
| Ciclopirox | 21 | $667 | $32 |
| Mometasone Furoate | 25 | $591 | $24 |
| Clotrimazole | 17 | $433 | $25 |
| Ipratropium | 17 | $393 | $23 |
| Mupirocin | 41 | $390 | $10 |
| Hydroxyzine | 28 | $349 | $12 |
| Albuterol Sulfate | 17 | $337 | $20 |
| Acyclovir | 12 | $131 | $11 |
| Levocetirizine Dihydrochloride | 12 | $101 | $8 |
| Cephalexin | 20 | $99 | $5 |
2015: 30 drugs
| Fluocinonide | 500 | $43,307 | $87 |
| Clobetasol Propionate | 181 | $38,846 | $215 |
| Econazole Nitrate | 128 | $31,889 | $249 |
| Acitretin | 22 | $30,615 | $1,392 |
| Otezla | 11 | $24,263 | $2,206 |
| Desonide | 92 | $16,843 | $183 |
| Calcipotriene | 40 | $15,605 | $390 |
| Doxycycline Hyclate | 76 | $6,171 | $81 |
| Fluorouracil | 25 | $5,461 | $218 |
| Metronidazole | 41 | $4,927 | $120 |
| Clindamycin Phosphate | 56 | $4,464 | $80 |
| Betamethasone Dipropionate | 55 | $3,649 | $66 |
| Ketoconazole | 101 | $3,547 | $35 |
| Triamcinolone Acetonide | 188 | $3,369 | $18 |
| Finacea | 13 | $3,310 | $255 |
| Desoximetasone | 16 | $2,893 | $181 |
| Tretinoin | 33 | $2,882 | $87 |
| Fluocinolone Acetonide | 28 | $2,851 | $102 |
| Selenium Sulfide | 88 | $1,693 | $19 |
| Permethrin | 16 | $1,268 | $79 |
| Hydrocortisone | 97 | $842 | $9 |
| Mupirocin | 63 | $694 | $11 |
| Minocycline | 34 | $677 | $20 |
| Hydroxyzine | 35 | $597 | $17 |
| Mometasone Furoate | 30 | $447 | $15 |
| Doxycycline Monohydrate | 23 | $327 | $14 |
| Ciclopirox | 12 | $301 | $25 |
| Acyclovir | 11 | $135 | $12 |
| Terbinafine | 15 | $120 | $8 |
| Cephalexin | 22 | $103 | $5 |
2014: 32 drugs
| Enbrel | 15 | $51,883 | $3,459 |
| Fluocinonide | 465 | $28,855 | $62 |
| Desonide | 120 | $24,553 | $205 |
| Calcipotriene | 46 | $20,646 | $449 |
| Acitretin | 21 | $19,036 | $906 |
| Clobetasol Propionate | 168 | $11,395 | $68 |
| Econazole Nitrate | 138 | $10,932 | $79 |
| Metronidazole | 70 | $8,639 | $123 |
| Doxycycline Hyclate | 56 | $6,412 | $114 |
| Tazorac | 15 | $5,913 | $394 |
| Clindamycin Phosphate | 59 | $4,588 | $78 |
| Fluorouracil | 20 | $3,674 | $184 |
| Triamcinolone Acetonide | 167 | $3,491 | $21 |
| Fluocinolone Acetonide | 29 | $3,260 | $112 |
| Imiquimod | 14 | $3,165 | $226 |
| Betamethasone Dipropionate | 36 | $2,483 | $69 |
| Desoximetasone | 12 | $2,007 | $167 |
| Tretinoin | 37 | $1,923 | $52 |
| Ketoconazole | 73 | $1,877 | $26 |
| Acyclovir | 12 | $1,299 | $108 |
| Selenium Sulfide | 72 | $1,276 | $18 |
| Doxycycline Monohydrate | 25 | $1,099 | $44 |
| Mupirocin | 79 | $960 | $12 |
| Hydroxyzine | 26 | $515 | $20 |
| Mometasone Furoate | 19 | $496 | $26 |
| Hydrocortisone | 55 | $414 | $8 |
| Doxepin | 18 | $308 | $17 |
| Minocycline | 20 | $292 | $15 |
| Hydroxychloroquine Sulfate | 13 | $287 | $22 |
| Cimetidine | 14 | $211 | $15 |
| Prednisone | 14 | $114 | $8 |
| Cephalexin | 15 | $90 | $6 |
2013: 29 drugs
| Soriatane | 23 | $25,783 | $1,121 |
| Fluocinonide | 490 | $22,858 | $47 |
| Desonide | 154 | $21,521 | $140 |
| Calcipotriene | 52 | $19,386 | $373 |
| Imiquimod | 26 | $8,109 | $312 |
| Acitretin | 11 | $7,640 | $695 |
| Metronidazole | 57 | $7,446 | $131 |
| Doxycycline Hyclate | 58 | $6,169 | $106 |
| Clobetasol Propionate | 169 | $5,826 | $34 |
| Tazorac | 13 | $5,389 | $415 |
| Clindamycin Phosphate | 56 | $5,145 | $92 |
| Triamcinolone Acetonide | 185 | $4,448 | $24 |
| Econazole Nitrate | 132 | $3,960 | $30 |
| Fluorouracil | 20 | $3,678 | $184 |
| Fluocinolone Acetonide | 37 | $3,440 | $93 |
| Betamethasone Dipropionate | 41 | $2,788 | $68 |
| Ketoconazole | 116 | $2,684 | $23 |
| Hydroxyzine | 69 | $1,649 | $24 |
| Desoximetasone | 15 | $1,546 | $103 |
| Permethrin | 17 | $1,430 | $84 |
| Selenium Sulfide | 85 | $1,318 | $16 |
| Mupirocin | 94 | $1,198 | $13 |
| Tretinoin | 35 | $1,042 | $30 |
| Hydrocortisone | 51 | $648 | $13 |
| Doxycycline Monohydrate | 22 | $560 | $25 |
| Fluticasone Propionate | 11 | $429 | $39 |
| Minocycline | 19 | $330 | $17 |
| Cephalexin | 24 | $162 | $7 |
| Prednisone | 12 | $53 | $4 |
Money from drug and device companies
$2,827 in 2025
| 2025 | 21 | 102 | $750 | $2,827 |
| 2024 | 21 | 159 | None | $3,237 |
| 2023 | 20 | 117 | $760 | $2,847 |
| 2022 | 19 | 94 | $5,325 | $7,247 |
| 2021 | 18 | 82 | $4,300 | $5,667 |
| 2020 | 12 | 60 | $5,250 | $6,096 |
| 2019 | 18 | 106 | $17,430 | $19,782 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Skyrizi | $1,056 | 18 payments
|
| LEO Pharma | Adbry | $311 | 21 payments
|
| Pfizer | Cibinqo | $276 | 13 payments
|
| Genzyme | Dupixent | $238 | 5 payments
|
| Janssen Biotech | Tremfya | $219 | 7 payments
|
| Novartis Pharmaceuticals | Rhapsido | $127 | 4 payments
|
See all 102 published payments
| Abbvie | Meals · 2025-12-23 | Rinvoq | $8 |
| Abbvie | Meals · 2025-12-19 | Rinvoq | $27 |
| Novartis Pharmaceuticals | Meals · 2025-12-17 | Cosentyx | $34 |
| Merck Sharp & Dohme | Education · 2025-12-16 | None | $26 |
| LEO Pharma | Meals · 2025-12-15 | Adbry | $14 |
| LEO Pharma | Meals · 2025-12-15 | Adbry | $14 |
| Novartis Pharmaceuticals | Meals · 2025-12-09 | Rhapsido | $31 |
| Sun Pharmaceutical Industries | Meals · 2025-12-02 | Ilumya | $33 |
| LEO Pharma | Meals · 2025-11-26 | Adbry | $19 |
| Abbvie | Meals · 2025-11-19 | Skyrizi | $15 |
| Organon | Meals · 2025-11-18 | None | $18 |
| LEO Pharma | Meals · 2025-11-17 | Adbry | $12 |
| LEO Pharma | Meals · 2025-11-12 | Anzupgo | $25 |
| Abbvie | Meals · 2025-11-06 | Skyrizi | $30 |
| Novartis Pharmaceuticals | Meals · 2025-11-05 | Rhapsido | $34 |
| Pfizer | Meals · 2025-10-16 | Cibinqo | $21 |
| LEO Pharma | Meals · 2025-10-15 | Anzupgo | $26 |
| Pfizer | Meals · 2025-10-14 | Cibinqo | $31 |
| LEO Pharma | Meals · 2025-10-13 | Adbry | $13 |
| LEO Pharma | Meals · 2025-09-30 | Adbry | $12 |
| Novartis Pharmaceuticals | Meals · 2025-09-29 | Cosentyx | $28 |
| Ucb | Meals · 2025-09-29 | Bimzelx | $19 |
| Sun Pharmaceutical Industries | Meals · 2025-09-25 | Ilumya | $25 |
| Sun Pharmaceutical Industries | Meals · 2025-09-24 | Leqselvi | $22 |
| Abbvie | Meals · 2025-09-16 | Skyrizi | $11 |
| LEO Pharma | Meals · 2025-09-16 | Adbry | $3 |
| LEO Pharma | Meals · 2025-09-16 | Adbry | $12 |
| Incyte | Meals · 2025-09-05 | Opzelura | $15 |
| LEO Pharma | Meals · 2025-09-05 | Adbry | $17 |
| Pfizer | Meals · 2025-09-03 | Litfulo | $31 |
| Regeneron Healthcare Solutions | Meals · 2025-08-27 | Dupixent | $27 |
| Arcutis Biotherapeutics | Meals · 2025-08-21 | Zoryve | $20 |
| Pfizer | Meals · 2025-08-19 | Cibinqo | $23 |
| Verrica Pharmaceuticals | Meals · 2025-08-18 | Ycanth | $17 |
| Abbvie | Meals · 2025-08-15 | Skyrizi | $18 |
| Abbvie | Meals · 2025-08-08 | Rinvoq | $29 |
| LEO Pharma | Meals · 2025-08-08 | Adbry | $26 |
| Organon | Meals · 2025-08-05 | None | $9 |
| Incyte | Meals · 2025-07-30 | Opzelura | $29 |
| Pfizer | Meals · 2025-07-22 | Cibinqo | $13 |
| LEO Pharma | Meals · 2025-07-16 | Adbry | $9 |
| Abbvie | Meals · 2025-07-03 | Skyrizi | $11 |
| Pfizer | Meals · 2025-07-02 | Litfulo | $7 |
| Ortho Dermatologics a division of Bausch Health US | Meals · 2025-06-30 | Siliq | $18 |
| Pfizer | Meals · 2025-06-26 | Cibinqo | $20 |
| Abbvie | Meals · 2025-06-24 | Skyrizi | $10 |
| Abbvie | Meals · 2025-06-23 | Rinvoq | $17 |
| LEO Pharma | Meals · 2025-06-20 | Adbry | $15 |
| STRATA Skin Sciences | Meals · 2025-06-17 | Xtrac | $16 |
| LEO Pharma | Meals · 2025-06-12 | Adbry | $12 |
| Janssen Biotech | Meals · 2025-06-10 | Tremfya | $10 |
| LEO Pharma | Meals · 2025-06-06 | Adbry | $9 |
| LEO Pharma | Meals · 2025-05-22 | Adbry | $9 |
| Sun Pharmaceutical Industries | Meals · 2025-05-20 | Winlevi | $25 |
| Janssen Scientific Affairs | Meals · 2025-05-14 | Tremfya | $13 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-13 | Sotyktu | $21 |
| Abbvie | Meals · 2025-05-13 | Skyrizi | $8 |
| Pfizer | Meals · 2025-05-12 | Cibinqo | $20 |
| Pfizer | Meals · 2025-05-08 | Cibinqo | $29 |
| LEO Pharma | Meals · 2025-05-05 | Adbry | $25 |
| Abbvie | Meals · 2025-05-01 | Skyrizi | $9 |
| Regeneron Healthcare Solutions | Meals · 2025-04-30 | Libtayo | $34 |
| Janssen Biotech | Meals · 2025-04-24 | Tremfya | $14 |
| Genzyme | Meals · 2025-04-24 | Dupixent | $14 |
| Pfizer | Meals · 2025-04-23 | Cibinqo | $30 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-03 | Sotyktu | $19 |
| Genzyme | Meals · 2025-04-03 | Dupixent | $27 |
| LEO Pharma | Meals · 2025-03-31 | Adbry | $19 |
| Abbvie | Meals · 2025-03-28 | Skyrizi | $18 |
| Organon | Meals · 2025-03-20 | Vtama | $7 |
| Genzyme | Meals · 2025-03-18 | None | $150 |
| LEO Pharma | Meals · 2025-03-13 | Adbry | $12 |
| Janssen Biotech | Meals · 2025-03-12 | Tremfya | $2 |
| Janssen Biotech | Meals · 2025-03-12 | Tremfya | $14 |
| Abbvie | Meals · 2025-03-12 | Skyrizi | $23 |
| Genzyme | Meals · 2025-03-12 | Dupixent | $30 |
| Genzyme | Meals · 2025-03-11 | Dupixent | $17 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-08 | Sotyktu | $30 |
| Janssen Biotech | Meals · 2025-03-06 | Tremfya | $150 |
| Abbvie | Meals · 2025-03-06 | Skyrizi | $15 |
| Amgen | Meals · 2025-03-06 | Otezla | $22 |
| Ucb | Meals · 2025-02-27 | Bimzelx | $13 |
| Pfizer | Meals · 2025-02-17 | Cibinqo | $26 |
| STRATA Skin Sciences | Meals · 2025-02-17 | Xtrac | $7 |
| Pfizer | Education · 2025-02-14 | Litfulo | $2 |
| Organon | Meals · 2025-02-12 | Vtama | $7 |
| Organon | Meals · 2025-02-12 | Vtama | $9 |
| LEO Pharma | Meals · 2025-02-07 | Adbry | $10 |
| Biofrontera | Meals · 2025-02-03 | None | $15 |
| Organon | Meals · 2025-01-30 | Vtama | $5 |
| Organon | Meals · 2025-01-30 | Vtama | $5 |
| Amgen | Meals · 2025-01-29 | Otezla | $19 |
| Janssen Biotech | Meals · 2025-01-24 | Tremfya | $17 |
| Lilly USA | Meals · 2025-01-23 | Taltz | $15 |
| Janssen Biotech | Meals · 2025-01-22 | Tremfya | $11 |
| Abbvie | Consulting · 2025-01-15 | None | $750 |
| Amgen | Meals · 2025-01-14 | Otezla | $25 |
| Pfizer | Meals · 2025-01-08 | Cibinqo | $23 |
| Organon | Meals · 2025-01-07 | Vtama | $6 |
| Organon | Meals · 2025-01-07 | Vtama | $9 |
| Abbvie | Meals · 2025-01-06 | Skyrizi | $30 |
| Abbvie | Meals · 2025-01-02 | Skyrizi | $25 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,237
| Abbvie | Skyrizi | $694 | 32 payments
|
| Dermavant Sciences | Vtama | $447 | 27 payments
|
| Sun Pharmaceutical Industries | Winlevi | $321 | 7 payments
|
| Janssen Biotech | Tremfya | $291 | 10 payments
|
| LEO Pharma | Adbry | $239 | 22 payments
|
| Ortho Dermatologics a division of Bausch Health US | Cabtreo | $212 | 10 payments
|
| Amgen | Otezla | $209 | 11 payments
|
| Pfizer | Eucrisa | $156 | 10 payments
|
| Arcutis Biotherapeutics | Zoryve | $117 | 5 payments
|
| Genzyme | Dupixent | $106 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $67 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $65 | 3 payments
|
| Galderma Laboratories L.P. | Aklief | $60 | 3 payments
|
| Organogenesis | Puraply Am | $56 | 2 payments
|
| Ucb | Bimzelx | $53 | 3 payments
|
| Janssen Research & Development | None | $52 | 1 payment
|
| Lilly USA | Taltz | $24 | 1 payment
|
| STRATA Skin Sciences | Xtrac | $22 | 1 payment
|
| Janssen Scientific Affairs | Tremfya | $21 | 1 payment
|
| Incyte | Opzelura | $13 | 1 payment
|
| Biofrontera | Ameluz | $13 | 3 payments
|
2023: $2,847
| LEO Pharma AS | None | $760 | 1 payment
|
| LEO Pharma | Adbry | $423 | 30 payments
|
| AbbVie | Skyrizi | $239 | 13 payments
|
| Dermavant Sciences | Vtama | $237 | 10 payments
|
| Lilly USA | Taltz | $171 | 12 payments
|
| Galderma Laboratories L.P. | Epiduo | $166 | 5 payments
|
| Ortho Dermatologics a division of Bausch Health US | Jublia | $143 | 9 payments
|
| Janssen Biotech | Tremfya | $136 | 6 payments
|
| Novartis Pharmaceuticals | Cosentyx | $131 | 4 payments
|
| Pfizer | Eucrisa | $112 | 11 payments
|
| Sun Pharmaceutical Industries | Ilumya | $49 | 2 payments
|
| Arcutis Biotherapeutics | None | $44 | 2 payments
|
| Amgen | Otezla | $43 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $41 | 2 payments
|
| Biofrontera | Ameluz | $39 | 3 payments
|
| Ucb | None | $30 | 1 payment
|
| Janssen Research & Development | None | $26 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $22 | 1 payment
|
| Organogenesis | Puraply | $21 | 1 payment
|
| STRATA Skin Sciences | Xtrac | $16 | 1 payment
|
2022: $7,247
| Abbvie | Skyrizi | $4,709 | 33 payments
|
| Eli Lilly and | None | $1,200 | 1 payment
|
| Janssen Biotech | Remicade | $196 | 13 payments
|
| LEO Pharma | Adbry | $192 | 16 payments
|
| Galderma Laboratories L.P. | None | $191 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Siliq | $152 | 6 payments
|
| Acrotech Biopharma | None | $103 | 1 payment
|
| Novartis Pharmaceuticals | Cosentyx | $98 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $64 | 3 payments
|
| Lilly USA | Taltz | $62 | 4 payments
|
| Pfizer | Cibinqo | $56 | 2 payments
|
| STRATA Skin Sciences | Xtrac | $41 | 1 payment
|
| Genzyme | Dupixent | $39 | 2 payments
|
| Allergan | Botox | $39 | 2 payments
|
| Sun Pharmaceutical Industries | Ilumya | $26 | 1 payment
|
| Journey Medical | Qbrexza | $23 | 1 payment
|
| EPI Health | Cloderm | $20 | 1 payment
|
| Incyte | Opzelura | $19 | 1 payment
|
| Amgen | Otezla | $18 | 1 payment
|
2021: $5,667
| Eli Lilly and | None | $2,300 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Arazlo | $1,331 | 11 payments
|
| Almirall | Klisyri | $842 | 4 payments
|
| AbbVie | Skyrizi | $349 | 19 payments
|
| Sun Pharmaceutical Industries | Absorica Ld | $158 | 14 payments
|
| Lilly USA | Taltz | $137 | 6 payments
|
| Pfizer | Eucrisa | $106 | 5 payments
|
| VYNE Pharmaceuticals | Amzeeq | $82 | 4 payments
|
| Organogenesis | Puraply Antimicrobial | $80 | 3 payments
|
| LEO Pharma | Enstilar | $50 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $49 | 2 payments
|
| Janssen Biotech | Remicade | $45 | 3 payments
|
| Bausch Health US | None | $45 | 1 payment
|
| Galderma Laboratories L.P. | Oracea | $30 | 2 payments
|
| Mayne Pharma | None | $19 | 1 payment
|
| Allergan | Botox | $17 | 1 payment
|
| Incyte | Opzelura | $14 | 1 payment
|
| EPI Health | Cloderm | $13 | 1 payment
|
2020: $6,096
| Pfizer | Eucrisa | $3,460 | 9 payments
|
| Journey Medical | None | $1,500 | 2 payments
|
| Ortho Dermatologics a division of Bausch Health US | Arazlo | $549 | 12 payments
|
| AbbVie | Skyrizi | $122 | 6 payments
|
| LEO Pharma | Enstilar | $119 | 14 payments
|
| Amgen | Otezla | $92 | 4 payments
|
| Sun Pharmaceutical Industries | Absorica Ld | $68 | 4 payments
|
| Mayne Pharma | Doryx | $55 | 3 payments
|
| Biofrontera | Ameluz | $39 | 2 payments
|
| Lilly USA | Taltz | $37 | 2 payments
|
| EPI Health | Sitavig | $31 | 1 payment
|
| Dermira | Qbrexza | $23 | 1 payment
|
2019: $19,782
| Dermira | Qbrexza | $7,884 | 9 payments
|
| Mayne Pharma | Lexette | $7,503 | 12 payments
|
| Pfizer | Eucrisa | $2,862 | 12 payments
|
| Ortho Dermatologics a division of Bausch Health US | Bryhali | $472 | 20 payments
|
| AbbVie | Humira | $226 | 11 payments
|
| Almirall | None | $150 | 2 payments
|
| Janssen Biotech | Tremfya | $129 | 10 payments
|
| Amgen | Enbrel | $82 | 5 payments
|
| Novartis Pharmaceuticals | Cosentyx | $81 | 4 payments
|
| Biofrontera | Ameluz | $80 | 4 payments
|
| Lilly USA | Taltz | $75 | 3 payments
|
| Sun Pharmaceutical Industries | Ilumya | $65 | 3 payments
|
| Galderma Laboratories L.P. | Epiduo Forte | $42 | 3 payments
|
| EPI Health | Sitavig | $37 | 3 payments
|
| DUSA Pharmaceuticals | Levulan Kerastick | $30 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $23 | 1 payment
|
| Celgene | Otezla | $21 | 1 payment
|
| Promius Pharma | Sernivo | $20 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Allergan, Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy in Subjects With Glabellar Frown Lines · 2020 | Their institution | $361,467 |
| Amgen Inc. · Interchangeability Study - Abp 654 · 2021 | Their institution | $218,258 |
| Eli Lilly and Company · A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab To Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis · 2019 | Their institution | $213,525 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Study About How Well Tak-279 Works and Its Safety in Participants With Moderate-To-Severe Plaque Psoriasis During 52 Weeks of Treatment · 2024 | Their institution | $127,751 |
| Vanda Pharmaceuticals Inc. · An Open Label, Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Trichostatin A in Healthy Volunteers · 2024 | Their institution | $116,983 |
| Incyte Corporation · A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo · 2025 | Their institution | $109,897 |
| Kiniksa Pharmaceuticals, Ltd. · A Phase 2a/B, Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of Kpl-716 in Reducing Pruritis in Subjects With Prurigo Nodularis · 2021 | Their institution | $102,201 |
| Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata · 2020 | Their institution | $100,338 |
| Incyte Corporation · A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo · 2024 | Their institution | $89,857 |
| Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over A 68-Week Treatment Period in Adult Patients With Moderate To Severe Hidradenitis Sup · 2025 | Their institution | $89,177 |
| Incyte Corporation · True Ad2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis · 2019 | Their institution | $75,985 |
| Takeda Pharmaceuticals U.S.A., Inc. · Tak-279-Pso-3003 A Phase 3, Multi-Center, Open-Label Study To Evaluate the Efficacy, Safety, and Tolerability of Tak-279 in Subjects With Moderate To Severe Plaque Psoriasis · 2025 | Their institution | $74,504 |
| Eli Lilly and Company · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study of Ly4100511 (Dc-853) for the Treatment of Adult Participants With Moderate-To Severe Plaque Psoriasis · 2025 | Their institution | $74,418 |
| SANOFI US SERVICES INC. · A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group 48-Week Extension Study To Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered As Monotherapy By Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-To-Severe Atopic Dermatitis · 2025 | Their institution | $72,770 |
| Vanda Pharmaceuticals Inc. · An Open Label Study Evaluating the Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild To Severe Onychomycosis · 2025 | Their institution | $71,175 |
| Janssen Research & Development, LLC · A Phase 2a2b Multi Center Randomized Placebo and Active Comparator Controlled Double Blind Dose Ranging Study To Evaluate the Safety and Efficacy of Bermekimab Jnj77474462 for the Treatment of Subjects With Moderate To Severe Hidradenitis Suppurativa. · 2022 | Their institution | $69,126 |
| Incyte Corporation · Pd Effects and Predictive Biomarkers of Jak/Stat Inhibition With Ruxolitinib in Operable Head and Neck Squamous Cell Carcinoma-A Window of Opportunity Trial · 2020 | Their institution | $65,066 |
| Acrotech Biopharma Inc. · 2023 | Their institution | $62,101 |
| Teva Pharmaceuticals USA, Inc. · A Phase 1b, Open-Label Trial To Assess Safety and Exploratory Efficacy of Tev-53408 in Participants With Vitiligo · 2025 | Their institution | $61,022 |
| Sun Pharmaceutical Industries Inc. · A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study To Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate To Severe Plaque Psoriasis of the Scalp · 2020 | Their institution | $60,496 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Study About How Well Tak-279 Works and Its Safety in Participants With Moderate-To-Severe Plaque Psoriasis During 52 Weeks of Treatment · 2025 | Their institution | $59,937 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-To-Severe Atopic Dermatitis · 2023 | Their institution | $59,741 |
| Eli Lilly and Company · An Open-Label 24-Week Study To Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis and Skin of Color · 2023 | Their institution | $57,971 |
| Incyte Corporation · A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of Incb053914 in Combination With Incb050465 in Participants With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma · 2020 | Their institution | $56,694 |
| Janssen Research & Development, LLC · A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Jnj-77242113 for the Treatment of Participants With Moderate To Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment · 2024 | Their institution | $55,753 |
| Bausch Health US, LLC · Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Efficacysafety Study · 2019 | Their institution | $55,499 |
| Novartis Pharmaceuticals Corporation · A Randomized Subject and Investigator Blinded Placebo Controlled Multi Center Study in Parallel Groups To Assess the Efficacy and Safety of Lys006 in Patients With Moderate To Severe Inflammatory Acne · 2019 | Their institution | $54,969 |
| Journey Medical Corporation · Dfd-29-Cd-004 · 2023 | Their institution | $54,825 |
| Bausch Health US, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Clinical Study To Compare the Safety and Efficacy of Idp-126 Gel To Epiduo? Forte Gel (0.3% Adapalene/2.5% Bpo), in the Treatment of Acne Vulgaris · 2022 | Their institution | $54,158 |
| Allergan Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy in Subjects With Glabellar Frown Lines · 2019 | Their institution | $52,995 |
| Kiniksa Pharmaceuticals, Ltd. · A Phase 2a/B, Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of Kpl-716 in Reducing Pruritis in Subjects With Prurigo Nodularis · 2022 | Their institution | $52,709 |
| VYNE Pharmaceuticals Inc. · Serlopitant · 2020 | Their institution | $50,396 |
| Janssen Research & Development, LLC · Cnto1959pso3018 · 2023 | Their institution | $50,012 |
| AbbVie, Inc. · Skyrizi · 2019 | Their institution | $45,812 |
| SANOFI US SERVICES INC. · Efficacy, Safety, Pk, Biologics Monotherapy Study in Pts. With Moderate To Severe Ad · 2024 | Their institution | $45,803 |
| Kiniksa Pharmaceuticals, Ltd. · A Phase 2a/B, Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of Kpl-716 in Reducing Pruritis in Subjects With Prurigo Nodularis · 2023 | Their institution | $45,210 |
| Eli Lilly and Company · A Randomized, Double-Blind, Placebo Controlled Trial To Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate To Severe Atopic Dermatitis · 2021 | Their institution | $44,978 |
| Eli Lilly and Company · A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study To Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis · 2021 | Their institution | $44,812 |
| Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata · 2019 | Their institution | $43,053 |
| SUN PHARMACEUTICAL INDUSTRIES INC. · A Study To Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate To Severe Genital Psoriasis · 2025 | Their institution | $41,451 |
| Bausch Health US, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Clinical Study To Compare the Safety and Efficacy of Idp-126 Gel To Epiduo? Forte Gel (0.3% Adapalene/2.5% Bpo), in the Treatment of Acne Vulgaris · 2021 | Their institution | $41,110 |
| LEO Pharma AS · Tralokinumab Trial in Adjunct Setting · 2019 | Their institution | $39,011 |
| Janssen Research & Development, LLC · Cnto1959pso3018 · 2024 | Their institution | $38,519 |
| E.R. Squibb & Sons, L.L.C. · Phase 2b Poc Pso Study - A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study To Evaluate the Clinical Efficacy and Safety of Bms-986322 in Participants With Moderate-To-Severe Psoriasis · 2023 | Their institution | $36,083 |
| E.R. Squibb & Sons, L.L.C. · A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With An Induction Period Followed By A Randomized Maintenance Period To Evaluate the Clinical Efficacy and Safety of Bms-986165 in Subjects With Mod · 2020 | Their institution | $33,947 |
| Bausch Health US, LLC · Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study To Evaluate the Efficacy and Safety of Idp-124 Lotion for the Treatment of Moderate To Severe Atopic Dermatitis in Pediatric and Adult Subjects · 2019 | Their institution | $33,819 |
| Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata · 2021 | Their institution | $33,224 |
| Kiniksa Pharmaceuticals International, plc · A Phase 2a/B, Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of Kpl-716 in Reducing Pruritis in Subjects With Prurigo Nodularis · 2024 | Their institution | $32,673 |
| Bausch Health US, LLC · A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of Idp-126 Gel in the Treatment of Acne Vulgaris · 2020 | Their institution | $30,777 |
| Taro Pharmaceuticals USA, Inc. · A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study To Evaluate the Efficacy and Safety of As012 in Subjects With Non-Segmental Vitiligo · 2021 | Their institution | $28,580 |
| Incyte Corporation · An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo · 2023 | Their institution | $27,948 |
| SANOFI US SERVICES INC. · A Phase 2, Randomized, Double-Blind, Placebo--Controlled, Parallel Group, 3-Arm, Multinational, Multicenter, Proof-of-Concept Study To Evaluate the Efficacy and Safety of Amlitelimab Monotherapy By Subcutaneous Injection in Adult Participants With Severe Alopecia Areata · 2025 | Their institution | $27,537 |
| Incyte Corporation · An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo · 2024 | Their institution | $26,825 |
| Eli Lilly and Company · A Long-Term Study To Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis · 2022 | Their institution | $24,821 |
| Eli Lilly and Company · A Long-Term Study To Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis · 2021 | Their institution | $24,556 |
| Teva Pharmaceuticals USA, Inc. · Study Comparing Tapinarof Cream 1% To Vtama (Tapinarof Cream 1%) in the Treatment of Plaque Psoriasis · 2025 | Their institution | $24,290 |
| Eli Lilly and Company · A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Patients With Moderate-To-Severe Atopic Dermatitis · 2021 | Their institution | $23,577 |
| Bausch Health US, LLC · A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of Idp-126 Gel in the Treatment of Acne Vulgaris · 2021 | Their institution | $22,465 |
| Eli Lilly and Company · A Multicenter, Open-Label, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate To Severe Atopic Dermatitis · 2019 | Their institution | $22,405 |
| SANOFI US SERVICES INC. · A Long-Term Extension Study To Evaluate the Long-Term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate To Severe Atopic Dermatitis Who Participated in Ky1005-Ct05 (Dri17366) · 2025 | Their institution | $22,257 |
| Eli Lilly and Company · A Randomized, Double-Blind, Placebo Controlled Trial To Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate To Severe Atopic Dermatitis · 2020 | Their institution | $22,163 |
| Galderma Research & Development, LLC · Evaluation of Acne-Induced Hyperpigmentation During Treatment of Acne Vulgaris Subjects With Trifarotene 50 G/G Cream Versus Vehicle Cream Over 24 Weeks · 2023 | Their institution | $21,311 |
| Bausch Health US, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Vehiclecontrolled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of Idp-126 Gel in the Treatment of Acne Vulgaris · 2019 | This clinician | $21,215 |
| SUN PHARMACEUTICAL INDUSTRIES INC. · Rxlc 2118 · 2024 | Their institution | $20,757 |
| SANOFI US SERVICES INC. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Proof-of-Concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate To Severe Hidradenitis Suppurativa · 2024 | Their institution | $20,300 |
| SANOFI US SERVICES INC. · A Phase 2, Randomized, Double-Blind, Placebo--Controlled, Parallel Group, 3-Arm, Multinational, Multicenter, Proof-of-Concept Study To Evaluate the Efficacy and Safety of Amlitelimab Monotherapy By Subcutaneous Injection in Adult Participants With Severe Alopecia Areata · 2024 | Their institution | $19,585 |
| Allergan, Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy in Subjects With Glabellar Frown Lines · 2021 | Their institution | $19,491 |
| Incyte Corporation · True Ad2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis · 2021 | Their institution | $18,818 |
| Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 2 (True-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2022 | Their institution | $18,718 |
| SUN PHARMACEUTICAL INDUSTRIES INC. · Efficacy and Safety of Ilumya in the Treatment of Scalp Psoriasis · 2021 | Their institution | $18,279 |
| SANOFI US SERVICES INC. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 3-Arm, Multinational, Multicenter Study To Evaluate the Efficacy and Safety of Amlitelimab By Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-To-Severe Atopic Dermatitis (Ad) Who Are on Background Topical Corticosteroids and Have Had An Inadequate Response To Prior Biologic Therapy Or Oral Janus Kinase (Jak) Inhibitor Treatment · 2025 | Their institution | $17,800 |
| Taro Pharmaceuticals USA, Inc. · A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study To Evaluate the Efficacy and Safety of As012 in Subjects With Non-Segmental Vitiligo · 2022 | Their institution | $17,395 |
| Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 2 (True-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2021 | Their institution | $17,363 |
| LEO Pharma AS · Long-Term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - Ecztend · 2019 | Their institution | $17,362 |
| Eli Lilly and Company · A Randomized, Double-Blind, Placebo Controlled Trial To Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate To Severe Atopic Dermatitis · 2022 | Their institution | $17,340 |
| Arcutis Biotherapeutics, Inc. · A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of Arq-151 Cream 0.3% in Subjects With Chronic Plaque Psoriasis Who Have Completed Preceding Studies Arq-151-301 Or Arq-151-302 · 2023 | Their institution | $17,132 |
| Janssen Research & Development, LLC · Study of Guselkumab in Skin of Color Participants With Moderate-To-Severe Plaque and/?Or Scalp Psoriasis (Visible) · 2025 | Their institution | $16,804 |
| Taro Pharmaceuticals USA, Inc. · Rxlc 2118 · 2023 | Their institution | $16,786 |
| Incyte Corporation · A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study To Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo · 2021 | Their institution | $16,374 |
| AbbVie, Inc. · 2019 | Their institution | $16,062 |
| Janssen Research & Development, LLC · A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Jnj-77242113 for the Treatment of Participants With Moderate To Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment · 2025 | Their institution | $15,933 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-To-Severe Atopic Dermatitis · 2024 | Their institution | $15,532 |
| Novartis Pharmaceuticals Corporation · A Randomized Subject and Investigator Blinded Placebo Controlled Multi Center Study in Parallel Groups To Assess the Efficacy and Safety of Lys006 in Patients With Moderate To Severe Inflammatory Acne · 2021 | Their institution | $15,410 |
| Acrotech Biopharma Inc. · 2024 | Their institution | $15,190 |
| VYNE Pharmaceuticals Inc. · 2020 | Their institution | $14,971 |
| Eli Lilly and Company · A Long-Term Study To Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis · 2025 | Their institution | $14,549 |
| Novartis Pharmaceuticals Corporation · A Multicenter, Randomized, Participant- and Investigator -Blinded, Placebo-Controlled, Phase 2a Study To Assess the Efficacy, Safety and Tolerability of Gia632 in Adult Participants With Moderate To Severe Atopic Dermatitis · 2025 | Their institution | $14,251 |
| SUN PHARMACEUTICAL INDUSTRIES INC. · Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis · 2022 | Their institution | $14,019 |
| Eli Lilly and Company · A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Atopic Dermatitis · 2021 | Their institution | $13,948 |
| SANOFI US SERVICES INC. · Registry To Characterize the Patients Who Receive Dupixent for Pn in A Real-World Setting · 2024 | Their institution | $13,778 |
| Bausch Health US, LLC · A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of Idp-120 Gel and Idp-120 Vehicle Gel in the Treatment of Acne Vulgaris · 2020 | Their institution | $13,742 |
| Bausch Health US, LLC · A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Study To Evaluate the Efficacy and Safety of Idp-124 Lotion for the Treatment of Moderate To Severe Atopic Dermatitis in Pediatric and Adult Subjects · 2020 | Their institution | $12,965 |
| E.R. Squibb & Sons, L.L.C. · A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment To Evaluate the Efficacy and Safety of Bms-986165 in Subjects With Moderate-To-Severe Plaque Psoriasis · 2023 | Their institution | $12,848 |
| Novartis Pharmaceuticals Corporation · A US Phase 3b, Multi-Center, Randomized, Double-Blind, Double-Dummy Study To Evaluate Efficacy of Remibrutinib Compared To Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled By Second Generation H1-Antihista · 2025 | Their institution | $12,772 |
| DERMIRA, INC. · A Randomized, Double-Blind, Placebo Controlled Trial To Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate To Severe Atopic Dermatitis · 2020 | Their institution | $12,764 |
| Eli Lilly and Company · A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Patients With Moderate-To-Severe Atopic Dermatitis · 2020 | Their institution | $12,237 |
| Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate To Severe Atopic Dermatitis · 2019 | Their institution | $12,167 |
| Eli Lilly and Company · A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Psoriasis · 2021 | Their institution | $12,104 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3b/4 Multi-Center, Randomized, Open-Label, Long-Term Safety Study of Deucravacitinib in Comparison To Ustekinumab in Participants With Moderate-To-Severe Plaque Psoriasis (Pragmatyk) · 2025 | Their institution | $12,000 |
| SANOFI US SERVICES INC. · A Phase 2, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Efficacy and Safety of Sar441566 in Adults With Moderate To Severe Plaque Psoriasis · 2024 | Their institution | $12,000 |
| Eli Lilly and Company · An Open-Label, 24-Week Study To Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis and Skin of Color · 2025 | Their institution | $11,991 |
| E.R. Squibb & Sons, L.L.C. · A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With An Induction Period Followed By A Randomized Maintenance Period To Evaluate the Clinical Efficacy and Safety of Bms-986165 in Subjects With Moderate To Severe Psoriasis · 2019 | Their institution | $11,978 |
| Eli Lilly and Company · A Phase 2b, Double-Blind, Placebo-Controlled Study To Evaluate Eltrekibart in Adult Participants With Moderate To Severe Hidradenitis Suppurativa · 2024 | Their institution | $11,800 |
| Vanda Pharmaceuticals Inc. · Evaluating the Effects of Tradipitant Vs. Placebo in Atopic Dermatitis · 2019 | Their institution | $11,691 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase 3, Multicenter, Open-Label Study To Evaluate the Long-Term Safety, Tolerability, and Efficacy of Tak-279 in Subjects With Moderate-To-Severe Plaque Psoriasis · 2024 | Their institution | $11,555 |
| SUN PHARMACEUTICAL INDUSTRIES INC. · Study To Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata · 2025 | Their institution | $11,315 |
| Eli Lilly and Company · Observation Priority E Short - Lebrikizumab - Atopic Dermatitis · 2025 | Their institution | $11,102 |
| SANOFI US SERVICES INC. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (Lsc) in Adults · 2025 | Their institution | $10,800 |
| Journey Medical Corporation · Dfd-29-Cd-004 · 2022 | Their institution | $10,600 |
| Incyte Corporation · A Study To Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis · 2024 | Their institution | $10,494 |
| Acrotech Biopharma Inc. · Medi-Mm36-302 · 2024 | Their institution | $10,309 |
| PFIZER INC. · A Phase 3 Randomized Doubleblind 52week Placebocontrolled Multicenter Study Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult and Adolescent Participants With Non Segmental Vitiligo · 2023 | Their institution | $10,107 |
| PFIZER INC. · A Phase 3 Randomized Doubleblind Vehiclecontrolled Study To Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction With Crisaborole Ointment 2 Once Daily Over 52 Weeks in Pediatric and Adult Participants Ages 3 Months and Older With Mildtomoderate Atopic Dermatitis Who Responded To Twice Daily Crisaborole Ointment 2 Treatment · 2021 | Their institution | $10,091 |
| Amgen Inc. · Ph2 Dax Discoid Lupus Dle Ole · 2024 | Their institution | $9,888 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-To-Severe Atopic Dermatitis · 2025 | Their institution | $9,357 |
| E.R. Squibb & Sons, L.L.C. · Phase II Umbrella Ad - A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, 5 Parallel-Group Study of Bms-986166 Or Branebrutinib for the Treatment of Patients With Moderate To Severe Atopic Dermatitis · 2023 | Their institution | $9,271 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Flare Prevention Phase III Trial in Gpp · 2020 | Their institution | $9,218 |
| SANOFI US SERVICES INC. · Registry To Characterize the Patients Who Receive Dupixent for Pn in A Real-World Setting · 2025 | Their institution | $9,073 |
| Eli Lilly and Company · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study of Ly4100511 (Dc-853) for the Treatment of Adult Participants With Moderate-To Severe Plaque Psoriasis · 2024 | Their institution | $9,000 |
| Dermavant Sciences, Inc. · A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate To Severe Atopic Dermatitis in Children With Adults · 2023 | Their institution | $8,836 |
| AbbVie Inc. · Skyrizi · 2020 | Their institution | $8,805 |
| SANOFI US SERVICES INC. · A Phase Iib, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Dose Ranging Study of A Subcutaneous Anti-Ox40l Monoclonal Antibody (Ky1005) in Moderate To Severe Atopic Dermatitis · 2022 | Their institution | $8,777 |
| Dr.Reddy's Laboratories,Inc. · Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 Week Study To Assess the Efficacy and Safety of Ppc-06, Extended Release Tablets in Moderate To Severe Plaque Psoriasis · 2019 | Their institution | $8,206 |
| Eli Lilly and Company · A Long-Term Study To Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis · 2023 | Their institution | $8,039 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Study About How Well Tak-279 Works and Its Safety in Participants With Moderate-To-Severe Plaque Psoriasis During 52 Weeks of Treatment · 2023 | Their institution | $8,000 |
| E.R. Squibb & Sons, L.L.C. · Phase 2b Poc Pso Study - A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study To Evaluate the Clinical Efficacy and Safety of Bms-986322 in Participants With Moderate-To-Severe Psoriasis · 2024 | Their institution | $7,720 |
| Regeneron Pharmaceuticals, Inc. · A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of Regn3500 Administered To Adult Patients With Moderate-To- Severe Atopic Dermatitis · 2019 | Their institution | $7,681 |
| E.R. Squibb & Sons, L.L.C. · A Study of Bms-986166 Or Branebrutinib for the Treatment of Participants With Atopic Dermatitis · 2024 | Their institution | $7,589 |
| Novartis Pharmaceuticals Corporation · A Randomized Subject and Investigator Blinded Placebo Controlled Multi Center Study in Parallel Groups To Assess the Efficacy and Safety of Lys006 in Patients With Moderate To Severe Inflammatory Acne · 2020 | Their institution | $7,520 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Flare Prevention Phase III Trial in Gpp · 2021 | Their institution | $7,502 |
| Incyte Corporation · A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study To Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo · 2020 | Their institution | $7,465 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate To Severe Atopic Dermatitis · 2025 | Their institution | $7,400 |
| Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate To Severe Atopic Dermatitis · 2019 | This clinician | $7,360 |
| SANOFI US SERVICES INC. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Proof-of-Concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate To Severe Hidradenitis Suppurativa · 2025 | Their institution | $6,900 |
| Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 2 True-V2 A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2019 | Their institution | $6,868 |
| Janssen Research & Development, LLC · A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Deucravacitinib Active Comparator-Controlled Study To Evaluate the Efficacy and Safety of Jnj-77242113 for the Treatment of Participants With Moderate To Severe Plaque Psoriasis · 2024 | Their institution | $6,500 |
| Eli Lilly and Company · A Phase 3 16-Week Randomized Double-Blind Placebo-Controlled Parallel- Group Study To Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis · 2023 | Their institution | $6,410 |
| PFIZER INC. · A Randomized Doubleblind Placebocontrolled Study To Demonstrate the Efficacy and Longterm Safety of Pf04965842 With Topical Corticosteroids in Adult Patients With Moderatetosevere Atopic Dermatitis · 2019 | Their institution | $6,237 |
| Eli Lilly and Company · A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab To Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis · 2019 | This clinician | $6,151 |
| E.R. Squibb & Sons, L.L.C. · Phase II Umbrella Ad - A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, 5 Parallel-Group Study of Bms-986166 Or Branebrutinib for the Treatment of Patients With Moderate To Severe Atopic Dermatitis · 2022 | Their institution | $6,095 |
| PFIZER INC. · A Phase 2a Multicenter Randomized Doubleblind Placebocontrolled 16week Study Evaluating the Safety and Efficacy of Pf06650833 Pf06700841 and Pf06826647 in Adults With Moderate To Severe Hidradenitis Suppurativa · 2020 | Their institution | $5,620 |
| Incyte Corporation · A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of Incb054707 in Participants With Hidradenitis Suppurativa · 2021 | Their institution | $5,500 |
| Eli Lilly and Company · A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata · 2023 | Their institution | $5,460 |
| PFIZER INC. · Prevention of Atopic Dermatitis Flare With Treatment of Crisaborole · 2019 | Their institution | $5,375 |
| Taro Pharmaceuticals USA, Inc. · A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study To Evaluate the Efficacy and Safety of As012 in Subjects With Non-Segmental Vitiligo · 2023 | Their institution | $5,375 |
| Amgen Inc. · Interchangeability Study Abp 654 · 2022 | Their institution | $5,344 |
| Incyte Corporation · An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo · 2025 | Their institution | $5,161 |
| Eli Lilly and Company · A Long-Term Study To Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis · 2020 | Their institution | $5,150 |
| Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate To Severe Atopic Dermatitis · 2020 | Their institution | $5,050 |
| Regeneron Pharmaceuticals, Inc. · A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of Regn3500 Administered To Adult Patients With Moderate-To- Severe Atopic Dermatitis · 2020 | Their institution | $5,011 |
| ABBVIE INC. · A Study To Assess Adverse Events of Intramuscular Agn-151586 Injection in Adult Participants With Glabellar Lines · 2022 | Their institution | $5,000 |
| PFIZER INC. · A Phase 3 Randomized Doubleblind Placebocontrolled Multicenter Study Investigating the Efficacy and Safety Ofpf04965842 Coadministered With Background Medicated Topical Therapy in Adolescent Participants 12 To 18 Years of Age With Moderatetosevere Atopic Dermatitis · 2020 | Their institution | $5,000 |
| LEO Pharma AS · Efficacy and Safety of Leo 43204 in Field Treatment of Actinic Keratosis on Face Or Chest Including 12-Month Follow-Up · 2019 | Their institution | $4,719 |
| UCB SA · A Phase 3, Randomized, Double-Blind, Placebocontrolled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate To Severe Hidradenitis Suppurativa · 2020 | Their institution | $4,558 |
| Eli Lilly and Company · A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab To Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis · 2020 | Their institution | $4,426 |
| ABBVIE INC. · A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared To Secukinumab for the Treatment of Adult Subjects With Moderate To Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy · 2021 | Their institution | $4,150 |
| Regeneron Pharmaceuticals, Inc. · A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of Regn3500 Administered To Adult Patients With Moderate-To- Severe Atopic Dermatitis · 2021 | Their institution | $4,064 |
| Janssen Research & Development, LLC · A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Jnj-77242113 for the Treatment of Participants With Moderate To Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment · 2023 | Their institution | $4,000 |
| PFIZER INC. · An Openlabel Extension Study To Assess the Longterm Safety and Efficacy of Pf04965842 in Adult Patients With Moderatetosevere Atopic Dermatitis · 2019 | Their institution | $3,897 |
| Amgen Inc. · Interchangeability Study Abp 654 · 2024 | Their institution | $3,690 |
| Eli Lilly and Company · An Open-Label, 24-Week Study To Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis and Skin of Color · 2024 | Their institution | $3,604 |
| Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata · 2022 | Their institution | $3,360 |
| Vanda Pharmaceuticals Inc. · Evaluating the Effects of Tradipitant Vs. Placebo in Atopic Dermatitis · 2020 | Their institution | $3,330 |
| Amgen Inc. · P2 Moderate-Severe Pdle · 2025 | Their institution | $3,275 |
| Janssen Research & Development, LLC · Noprodnap0029 · 2023 | Their institution | $3,273 |
| Incyte Corporation · A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study To Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo · 2023 | Their institution | $3,229 |
| Janssen Research & Development, LLC · A Phase 2a2b Multi Center Randomized Placebo and Active Comparator Controlled Double Blind Dose Ranging Study To Evaluate the Safety and Efficacy of Bermekimab Jnj77474462 for the Treatment of Subjects With Moderate To Severe Hidradenitis Suppurativa. · 2023 | Their institution | $3,224 |
| Dermavant Sciences, Inc. · An Open Label, Long-Term Extension Study To Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis · 2024 | Their institution | $3,094 |
| LEO Pharma AS · Tralokinumab: Trial in Adjunct Setting · 2020 | Their institution | $3,040 |
| Dr.Reddy's Laboratories,Inc. · Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 Week Study To Assess the Efficacy and Safety of Ppc-06, Extended Release Tablets in Moderate To Severe Plaque Psoriasis · 2020 | Their institution | $3,000 |
| LEO Pharma AS · Long-Term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - Ecztend · 2020 | Their institution | $2,829 |
| PFIZER INC. · A Phase 3 Randomized Doubleblind Vehiclecontrolled Study To Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction With Crisaborole Ointment 2 Once Daily Over 52 Weeks in Pediatric and Adult Participants Ages 3 Months and Older With Mildtomoderate Atopic Dermatitis Who Responded To Twice Daily Crisaborole Ointment 2 Treatment · 2022 | Their institution | $2,743 |
| PFIZER INC. · Prevention of Atopic Dermatitis Flare With Treatment of Crisaborole · 2020 | Their institution | $2,742 |
| SANOFI US SERVICES INC. · A Phase Iib, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Dose Ranging Study of A Subcutaneous Anti-Ox40l Monoclonal Antibody (Ky1005) in Moderate To Severe Atopic Dermatitis · 2024 | Their institution | $2,693 |
| LEO Pharma AS · Long Term Study Leo 90100 on the Body · 2019 | Their institution | $2,637 |
| Eli Lilly and Company · An Open-Label Study To Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis Previously Treated With Dupilumab · 2023 | Their institution | $2,502 |
| Eli Lilly and Company · A Multicenter, Open-Label, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate To Severe Atopic Dermatitis · 2020 | Their institution | $2,500 |
| Dermavant Sciences, Inc. · An Open Label, Long-Term Extension Study To Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis · 2023 | Their institution | $2,500 |
| PFIZER INC. · A Phase 3 Randomized Doubleblind 52week Placebocontrolled Multicenter Study Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult and Adolescent Participants With Non Segmental Vitiligo · 2022 | Their institution | $2,495 |
| Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata · 2020 | This clinician | $2,341 |
| Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 2 (True-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2019 | Their institution | $2,284 |
| AbbVie, Inc. · Humira · 2019 | Their institution | $2,150 |
| AbbVie Inc. · Humira · 2020 | Their institution | $2,150 |
| Incyte Corporation · A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of Incb054707 in Participants With Hidradenitis Suppurativa · 2024 | Their institution | $2,130 |
| E.R. Squibb & Sons, L.L.C. · A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment To Evaluate the Efficacy and Safety of Bms-986165 in Subjects With Moderate-To-Severe Plaque Psoriasis · 2022 | Their institution | $2,062 |
| Eli Lilly and Company · A Phase 1 Double-Blind Randomized Placebo-Controlled Multiple-Dose Study To Evaluate the Safety Tolerability and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Atopic Dermatitis · 2023 | Their institution | $1,884 |
| ABBVIE INC. · Chronic Plaque Psoriasis (Ps) Registry · 2022 | Their institution | $1,790 |
| ABBVIE INC. · A 10-Year, Post-Marketing, Observational Study To Assess Long Term Safety of Humira (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (Ps) · 2021 | Their institution | $1,720 |
| Amgen Inc. · P2 Moderate-Severe Pdle · 2024 | Their institution | $1,622 |
| Eli Lilly and Company · A Multicenter, Open-Label, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate To Severe Atopic Dermatitis · 2019 | This clinician | $1,252 |
| E.R. Squibb & Sons, L.L.C. · A Study To Evaluate Effectiveness and Safety of Bms-986322 in Participants With Moderate-To-Severe Psoriasis · 2024 | Their institution | $1,160 |
| Incyte Corporation · A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study To Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo · 2022 | Their institution | $1,127 |
| E.R. Squibb & Sons, L.L.C. · A Study To Evaluate Effectiveness and Safety of Bms-986322 in Participants With Moderate-To-Severe Psoriasis · 2023 | Their institution | $1,110 |
| ABBVIE INC. · A Multicenter, Open Label Study To Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate To Severe Plaque Type Psoriasis (Limmitless) · 2023 | Their institution | $1,050 |
| Eli Lilly and Company · A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Patients With Moderate-To-Severe Atopic Dermatitis · 2022 | Their institution | $1,004 |
| E.R. Squibb & Sons, L.L.C. · A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment To Evaluate the Efficacy and Safety of Bms-986165 in Subjects With Moderate-To-Severe Plaque Psoriasis · 2021 | Their institution | $1,000 |
| Bausch Health US, LLC · A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of Idp-123 Lotion and Idp-123 Vehicle Lotion in the Treatment of Acne Vulgaris · 2019 | Their institution | $975 |
| Eli Lilly and Company · An Open-Label, Study To Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis Previously Treated With Dupilumab · 2024 | Their institution | $840 |
| Eli Lilly and Company · An Open-Label 24-Week Study To Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis and Skin of Color · 2023 | This clinician | $790 |
| Amgen Inc. · P3 Ad Monotherapy Induction · 2023 | Their institution | $787 |
| Eli Lilly and Company · A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study To Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis · 2022 | Their institution | $776 |
| Janssen Research & Development, LLC · A Phase 2a2b Multi Center Randomized Placebo and Active Comparator Controlled Double Blind Dose Ranging Study To Evaluate the Safety and Efficacy of Bermekimab Jnj77474462 for the Treatment of Subjects With Moderate To Severe Hidradenitis Suppurativa. · 2024 | Their institution | $735 |
| Amgen Inc. · Astro P3 Ad Adolescent Mono · 2024 | Their institution | $661 |
| Eli Lilly and Company · A Long-Term Study To Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis · 2024 | Their institution | $552 |
| Incyte Corporation · A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo · 2023 | Their institution | $548 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Blind Placebo Controlled 52 Week Study To Demonstrate the Efficacy Safety and Tolerability of Subcutaneous Secukinumab Injections With 2 Ml Prefilled Syringes 300 Mg in Adult Subjects With Moderate To Severe Plaque Psoriasi · 2019 | Their institution | $500 |
| Incyte Corporation · A Study To Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis · 2025 | Their institution | $371 |
| PFIZER INC. · A Phase 3 Randomized Doubleblind Placebocontrolled Multicenter Study Investigating the Efficacy and Safety Ofpf04965842 Coadministered With Background Medicated Topical Therapy in Adolescent Participants 12 To 18 Years of Age With Moderatetosevere Atopic Dermatitis · 2019 | Their institution | $224 |
| Eli Lilly and Company · A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Psoriasis · 2020 | Their institution | $150 |
| Eli Lilly and Company · A Long-Term Study To Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis · 2021 | This clinician | $90 |
| SUN PHARMACEUTICAL INDUSTRIES INC. · Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis · 2023 | Their institution | $75 |
| Eli Lilly and Company · A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab To Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis · 2020 | This clinician | $33 |
| Eli Lilly Export S.A. Puerto Rico Branch · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Patients With Moderate To Severe Atopic Dermatitis · 2019 | Their institution | $14 |
| Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata · 2019 | This clinician | $5 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1326018987
- Licence
- CA G53340California G53340: Current · expires 2028-04-30
- Trained
- University of Southern California Keck School of Medicine, 1993
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 2557 Mowry Ave, Ste 34, Fremont, CA, 94538
- NPI first listed
- 2006-01-25
- NPI last updated
- 2010-10-01
This is when the NPI record was last certified, not a medical board exam.